Polyacenes with four ortho-fused benzene rings in a straight linear arrangement. This group is best known for the subclass called TETRACYCLINES.
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
Chemicals used in agriculture. These include pesticides, fumigants, fertilizers, plant hormones, steroids, antibiotics, mycotoxins, etc.
An anthrocycline from a Streptomyces nogalater variant. It is a cytolytic antineoplastic that inhibits DNA-dependent RNA synthesis by binding to DNA.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.
Therapeutic approach tailoring therapy for genetically defined subgroups of patients.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Conferences, conventions or formal meetings usually attended by delegates representing a special field of interest.
Societies whose membership is limited to physicians.
Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.
A subspecialty of internal medicine concerned with the study of neoplasms.
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
An antimitotic agent with immunosuppressive properties.
Agents that have a damaging effect on the HEART. Such damage can occur from ALKYLATING AGENTS; FREE RADICALS; or metabolites from OXIDATIVE STRESS and in some cases is countered by CARDIOTONIC AGENTS. Induction of LONG QT SYNDROME or TORSADES DE POINTES has been the reason for viewing some drugs as cardiotoxins.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
SUGARS containing an amino group. GLYCOSYLATION of other compounds with these amino sugars results in AMINOGLYCOSIDES.
Organic compounds that have a relatively high VAPOR PRESSURE at room temperature.
Spherical, heterogeneous aggregates of proliferating, quiescent, and necrotic cells in culture that retain three-dimensional architecture and tissue-specific functions. The ability to form spheroids is a characteristic trait of CULTURED TUMOR CELLS derived from solid TUMORS. Cells from normal tissues can also form spheroids. They represent an in-vitro model for studies of the biology of both normal and malignant cells. (From Bjerkvig, Spheroid Culture in Cancer Research, 1992, p4)
Specialized non-fenestrated tightly-joined ENDOTHELIAL CELLS with TIGHT JUNCTIONS that form a transport barrier for certain substances between the cerebral capillaries and the BRAIN tissue.
Uptake of substances through the SKIN.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS.
Exclusive legal rights or privileges applied to inventions, plants, etc.
A novel composition, device, or process, independently conceived de novo or derived from a pre-existing model.
A clear, odorless, tasteless liquid that is essential for most animal and plant life and is an excellent solvent for many substances. The chemical formula is hydrogen oxide (H2O). (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Property, such as patents, trademarks, and copyright, that results from creative effort. The Patent and Copyright Clause (Art. 1, Sec. 8, cl. 8) of the United States Constitution provides for promoting the progress of science and useful arts by securing for limited times to authors and inventors, the exclusive right to their respective writings and discoveries. (From Black's Law Dictionary, 5th ed, p1014)
The (+)-enantiomorph of razoxane.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow.
The hollow, muscular organ that maintains the circulation of the blood.
The level of governmental organization and function at the national or country-wide level.
A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.
A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).
Physical activity which is usually regular and done with the intention of improving or maintaining PHYSICAL FITNESS or HEALTH. Contrast with PHYSICAL EXERTION which is concerned largely with the physiologic and metabolic response to energy expenditure.
A regimen or plan of physical activities designed and prescribed for specific therapeutic goals. Its purpose is to restore normal musculoskeletal function or to reduce pain caused by diseases or injuries.
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

Novel selective inhibitors for human topoisomerase I, BM2419-1 and -2 derived from saintopin. (1/757)

Compounds BM2419-1 and -2 were isolated from a culture broth of a fungus Paecilomyces sp. BM2419. It was shown that these novel compounds were artifacts derived from saintopin, a dual inhibitor of topoisomerase I and II by independent processes. In the human topoisomerase I inhibition assay using the recombinant Saccharomyces cerevisiae, BM2419-1 and -2 inhibited selectively the yeast growth dependent on human topoisomerase I induction with IC50 values of 0.3 ng/ml and 6.0 ng/ml, respectively.  (+info)

Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line. (2/757)

The effects of 4-demethoxydaunorubicin (idarubicin, IDA) and MX2, a new morpholino-anthracycline, on up-regulation of the MDR1 gene in the low-level multidrug resistant (MDR) cell line CEM/A7R were compared at similar concentrations (IC10, IC50 and IC90) over a short time exposure (4 and 24 h). The chemosensitivity of each drug was determined by a 3-day cell growth inhibition assay. Compared with epirubicin (EPI), IDA and MX2 were 17- and eightfold more effective in the CEM/A7R line respectively. No cross-resistance to 5-FU was seen in the CEM/A7R line. Verapamil (5 microM) and PSC 833 (1 microM), which dramatically reversed resistance to EPI in the CEM/A7R line, had no sensitizing effect on the resistance of this line to MX2, but slightly decreased resistance to IDA. The sensitivity to 5-FU was unchanged by these modulators. The induction of MDR1 mRNA expression by IDA, MX2 and 5-FU was analysed by Northern blotting and semiquantitatively assessed by scanning Northern blots on a phosphorimager. The relative level of MDR1 expression was expressed as a ratio of MDR1 mRNA to the internal RNA control glyceraldehyde-3-phosphate dehydrogenase (GAPDH). IDA, MX2 and 5-FU differentially up-regulated MDR1 mRNA in the CEM/A7R line in a dose-dependent manner. Both IDA and MX2 induced MDR1 expression within 4 h. 5-FU up-regulated MDR1 expression only when drug exposure was prolonged to 24 h. Based on MRK 16 binding, flow cytometric analysis of P-glycoprotein (Pgp) expression paralleled the increase in MDR1 mRNA levels. For the three anthracyclines, the increase in MDR1 expression was stable in cells grown in the absence of drug for more than 3 weeks after drug treatment. The induction of MDR1 expression by 5-FU was transient, associated with a rapid decrease in the increased Pgp levels which returned to baseline 72 h after the removal of 5-FU. This study demonstrates that MDR1 expression can be induced by analogues of anthracyclines not pumped by Pgp, and that this induction appears to be stable despite a 3-week drug-free period.  (+info)

Characterization of aklavinone-11-hydroxylase from Streptomyces purpurascens. (3/757)

Aklavinone-11-hydroxylase (RdmE) is a FAD monooxygenase participating in the biosynthesis of daunorubicin, doxorubicin and rhodomycins. The rdmE gene encodes an enzyme of 535 amino acids. The sequence of the Streptomyces purpurascens enzyme is similar to other Streptomyces aromatic polyketide hydroxylases. We overexpressed the gene in Streptomyces lividans and purified aklavinone-11-hydroxylase to apparent homogeneity with four chromatographic steps utilizing a kinetic photometric enzyme assay. The enzyme is active as the monomer with a molecular mass of 60 kDa; it hydroxylates aklavinone and other anthracyclinones. Aklavinone-11-hydroxylase can use both NADH and NADPH as coenzyme but it is slowly inactivated in the presence of NADH. The apparent Km for NADPH is 2 mM and for aklavinone 10 microM. The enzyme is inactivated in the presence of phenylglyoxal and 2,3-butanedione. NADPH protects against inactivation of aklavinone-11-hydroxylase by phenylglyoxal.  (+info)

Barminomycin forms GC-specific adducts and virtual interstrand crosslinks with DNA. (4/757)

The sequence specificity of the binding of barminomycin (SN-07 chromophore) to DNA was investigated using an in vitro transcription assay. It was found that this compound formed blockages to transcription, and these blocks were highly selective for 5'-GC sequences. The half-lives of the first seven transcriptional blockages at 37 degrees C were 14-130 min, plus one site >>200 min, with widely varying levels of essentially permanent blockages at each site (0-100%; average of 40%), indicative of considerable dependence on flanking sequences of adducts stability at individual GC sites. Barminomycin was also shown to form DNA virtual (i.e. functional) interstrand crosslinks. Such crosslinks were also relatively heat stable, with 40% of the DNA remaining crosslinked after heating at 90 degrees C for 5 min. The barminomycin-DNA adducts and crosslinks appear to be essentially identical to those formed between adriamycin and DNA. Whereas adriamycin requires prior activation with formaldehyde in order to form adducts and crosslinks, barminomycin behaves in all respects as if it is a pre-activated form of adriamycin.  (+info)

Development of a self-cloning system for Actinomadura verrucosospora and identification of polyketide synthase genes essential for production of the angucyclic antibiotic pradimicin. (5/757)

A self-cloning system for Actinomadura verrucosospora, a producer of the angucyclic antibiotic pradimicin A (PRM A), has been developed. The system is based on reproducible and reliable protoplasting and regeneration conditions for A. verrucosospora and a novel plasmid vector that consists of a replicon from a newly found Actinomadura plasmid and a selectable marker cloned from the Actinomadura strain. The system has an efficiency of more than 10(5) CFU/microgram of DNA. Using this system, we have cloned and identified the polyketide synthase (PKS) genes essential for PRM A biosynthesis from A. verrucosospora. Nucleotide sequence analysis of the 3.5-kb SalI-SphI fragment showed that ketosynthase subunits (open reading frame 1 [ORF1] and ORF2) of the essential PKS genes have strong similarities (59 to 89%) to those for angucyclic antibiotic biosynthesis.  (+info)

Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. (6/757)

The expression of P-glycoprotein (Pgp) is often increased in acute myeloid leukemia (AML). However, little is known of the regulation of Pgp expression by cytotoxics in AML. We examined whether Pgp expression and function in leukemic blasts was altered after a short exposure to cytotoxics. Blasts were isolated from 19 patients with AML (15 patients) or chronic myeloid leukemia in blastic transformation (BT-CML, 4 patients). Pgp expression and function were analyzed by flow cytometric analysis of MRK 16 binding and Rhodamine 123 retention, respectively. At equitoxic concentrations, ex vivo exposure for 16 hours to the anthracyclines epirubicin (EPI), daunomycin (DAU), idarubicin (IDA), or MX2 or the nucleoside analogue cytosine arabinoside (AraC) differentially upregulated MDR1/Pgp expression in Pgp-negative and Pgp-positive blast cells. In Pgp-negative blasts, all four anthracyclines and AraC significantly increased Pgp expression (P =.01) and Pgp function (P =.03). In contrast, MX2, DAU, and AraC were the most potent in inducing Pgp expression and function in Pgp positive blasts (P <.05). A good correlation between increased Pgp expression and function was observed in Pgp-negative (r =.90, P =.0001) and Pgp-positive blasts (r =.77, P =.0002). This increase in Pgp expression and function was inhibited by the addition of 1 micromol/L PSC 833 to blast cells at the time of their exposure to these cytotoxics. In 1 patient with AML, an increase in Pgp levels was observed in vivo at 4 and 16 hours after the administration of standard chemotherapy with DAU/AraC. Upregulation of Pgp expression was also demonstrated ex vivo in blasts harvested from this patient before the commencement of treatment. In 3 other cases (1 patient with AML and 2 with BT-CML) in which blasts were Pgp negative at the time of initial clinical presentation, serial samples at 1 to 5 months after chemotherapy showed the presence of Pgp-positive blasts. All 3 patients had refractory disease. Interestingly, in all 3 cases, upregulation of Pgp by cytotoxics was demonstrated ex vivo in blasts harvested at the time of presentation. These data suggest that upregulation of the MDR1 gene may represent a normal response of leukemic cells to cytotoxic stress and may contribute to clinical drug resistance.  (+info)

Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein. (7/757)

Multidrug resistance (MDR) in model systems is known to be conferred by two different integral proteins, the 170-kDa P-glycoprotein (Pgp) and the 190-kDa multidrug resistance-associated protein (MRP1). One possible pharmacological approach to overcome drug resistance is the use of specific inhibitors, which enhance the cytotoxicity of known antineoplastic agents. However, while many compounds have been proven to be very efficient in inhibiting Pgp activity only some of them are able to inhibit MRP1. The other likely approach is based on the design and synthesis of new non-cross-resistant drugs with physicochemical properties favoring the uptake of the drug by the resistant cells. The intracellular drug retention influences its cytotoxic effect. The level of the intracellular drug content is a function of the amount of drug transported inside the cell (influx) and the amount of drug expelled from the cell (efflux). In this work, the kinetics of drug uptake and the kinetics of active efflux of several anthracycline derivatives in both Pgp expressing K562/Adr cells and MRP1 expressing GLC4/Adr cells was determined. Our data have shown that in both cell lines there is no correlation between the resistance factor and the kinetics of drug efflux by these pumping systems. However, a very good correlation between the resistance factor and the kinetics of drug uptake has been established in both cell lines: the resistance factor decreases when the kinetics of drug uptake increases. This work has clearly shown that when the rate of transmembrane transport of anthracycline is high enough, the efflux mediated by the protein transporter is not able to pace with it. The protein transporter essentially operates in a futile cycle and the resistance factor is tending to one. It does not mean, however, that when the resistance factor is close to one the anthracycline is not transported by the pump.  (+info)

Localization of a substrate specificity domain in the multidrug resistance protein. (8/757)

Multidrug resistance protein (MRP) confers resistance to a number of natural product chemotherapeutic agents. It is also a high affinity transporter of some physiological conjugated organic anions such as cysteinyl leukotriene C(4) and the cholestatic estrogen, 17beta-estradiol 17(beta-D-glucuronide) (E(2)17betaG). We have shown that the murine orthologue of MRP (mrp), unlike the human protein, does not confer resistance to common anthracyclines and is a relatively poor transporter of E(2)17betaG. We have taken advantage of these functional differences to identify region(s) of MRP involved in mediating anthracycline resistance and E(2)17betaG transport by generating mrp/MRP hybrid proteins. All hybrid proteins conferred resistance to the Vinca alkaloid, vincristine, when transfected into human embryonic kidney cells. However, only those in which the COOH-terminal third of mrp had been replaced with the corresponding region of MRP-conferred resistance to the anthracyclines, doxorubicin, and epirubicin. Exchange of smaller segments of the COOH-terminal third of the mouse protein by replacement of either amino acids 959-1187 or 1188-1531 with those of MRP produced proteins capable of conferring some level of resistance to the anthracyclines tested. All hybrid proteins transported cysteinyl leukotriene C(4) with similar efficiencies. In contrast, only those containing the COOH-terminal third of MRP transported E(2)17betaG with an efficiency comparable with that of the intact human protein. The results demonstrate that differences in primary structure of the highly conserved COOH-terminal third of mrp and MRP are important determinants of the inability of the murine protein to confer anthracycline resistance and its relatively poor ability to transport E(2)17betaG.  (+info)

All information about the latest scientific publications of the Clínica Universidad de Navarra. GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment
Genetic polymorphisms in drug-metabolizing enzymes have been linked to inter-individual differences in the efficacy and toxicity of many medications. The aim of our study was to reveal the association of MTHFR and GSTP1 gene polymorphisms with toxicity in breast cancer patients treated with adjuvant anthracycline-based treatment. The case group comprised 74 patients with breast cancer (median age: 48.9, range: 2769 years; stage: II-III). All patients received 6 cycles of adjuvant anthracycline-based chemotherapy regimen with 5-fluorouracil, adriamycin, and cyclophosphamide (FAC). Toxicity was assessed using NCI-CTC. The polymorphic variants of the MTHFR (c. 677 C>T) and GSTP1 (c. 313 A>G) were analyzed by Allelic Discrimination Real Time PCR using specific primers and TaqMan MGB probes. The genotypes distributions observed were similar to Hardy-Weinberg equilibrium expectations. The association between genotypes and toxicity was tested using univariate logistic regression and logistic regression ...
Figure 4. Bland-Altman analysis for intra-observer and inter-observer reliability.. Discussion. Anthracyclines, such as doxorubicin and epirubicin, have been used extensively and continue to be some of the most active cytotoxic agents available to treat a wide spectrum of hematologic malignancies and solid tumors, including acute myeloid, lymphoid leukemia, lymphoma and breast cancer. As a result of advances in the treatment of cancers, the number of survivors will fortunately continue to increase.. Unfortunately, despite their success in treating cancer, anthracyclines are limited by their serious toxic effects on the myocardium. Life altering cardiac sequelae from anthracyclines remain a problem, with a range of 5-23% of patients developing late-onset heart failure secondary to anthracycline-induced cardiotoxicity [10]. Reliable, sensitive and non-invasive method in detecting cardiac function is of vital importance during anthracycline administration.. Strain is a dimensionless parameter ...
TY - JOUR. T1 - Early cardiac changes following anthracycline chemotherapy in breast cancer: a prospective multi-centre study using advanced cardiac imaging and biochemical markers. AU - Grover, Suchi. AU - De Pasquale, Carmine. AU - Leong, Darryl. AU - Chakrabarty, Adhiraj. AU - Cheong, Kerry. AU - Kotasek, Dusan. AU - Joshi, Rohit. AU - Penhall, Amy. AU - Joerg, Lucas. AU - Joseph, Majo. AU - Koczwara, Bogda. AU - Selvanayagam, Joseph. PY - 2012. Y1 - 2012. M3 - Article. VL - 14. SP - 181. EP - 182. JO - Journal of Cardiovascular Magnetic Resonance. JF - Journal of Cardiovascular Magnetic Resonance. SN - 1097-6647. IS - S1. ER - ...
New data analyses found no association between anthracycline chemotherapy and greater risk of cognitive decline in breast cancer survivors, according to an article published online by JAMA Oncology.
The activity and tolerability of trabectedin has been widely studied in the second-line STS setting, but few studies evaluate it as first-line therapy for patients with comorbidities that preclude anthracycline-based chemotherapy. This study, TR1US, assessed the efficacy, tolerability, and pharmacokinetics of trabectedin in patients with STS in the latter group.. In this study, patients received trabectedin 1.3 to 1.5 mg/m2 as a 24-hour infusion every 3 weeks until progression or unacceptable toxicity. Response, progression-free survival (PFS), and overall survival (OS) were assessed per RECIST 1.1 and Kaplan-Meier, respectively. From February 2014 to December 2015, 24 patients were enrolled. Their median age was 78 years (range, 64-89 years). STS histologies were leiomyosarcoma (46%), liposarcoma (33%), and others (21%). Two patients had previously received adjuvant anthracycline-based chemotherapy. A median of 4 cycles of trabectedin were delivered.. Among the 24 patients, 2 achieved partial ...
Nakamori S, Jang J, Tschabrunn CM, Pierce P, Goddu B, Rodriguez J, Ngo LH, Tung NM, Manning WJ, Nezafat R. Noncontrast CMR for Detecting Early Myocardial Tissue Injury in a Swine Model of Anthracycline-Induced Cardiotoxicity. JACC Cardiovasc Imaging. 2019 10; 12(10):2085-2087 ...
Anthracyclines are among the most effective chemotherapy treatments available for various types of cancer. However, there is a risk of damage to the heart (cardiotoxicity) depending on the cumulative dose. Certain drugs might prevent this damage, but for many of these drugs, the review authors found no high quality evidence about whether they were effective in protecting the heart and they were unable to draw conclusions. For dexrazoxane, the review authors found 10 studies enrolling over 1600 patients. These studies provided evidence that dexrazoxane prevented heart damage without interfering with the anti-tumour effects of anthracycline treatment. Patients who got dexrazoxane with their anthracycline treatment had about one third of the risk of heart failure compared to patients who got anthracyclines without dexrazoxane. Dexrazoxane had no effect on survival. We cant be sure about whether it had any undesirable side effects.. ...
Anthracycline-based chemotherapy is widely used as adjuvant treatment for breast cancer. In addition to the challenge posed by anthracycline-induced cardiotoxicity, there are issues surrounding previous treatment with anthracyclines which limit its utility in the metastatic disease setting. Many patients with advanced disease will have had prior anthracycline-based adjuvant therapy, may have reached a maximum cumulative lifetime dose, or developed refractory disease, creating an obvious need for non-anthracycline treatment strategies.3 Platinum- and taxane-based chemotherapies as first-line therapy for metastatic breast cancer have demonstrated significant activity, producing single-agent response rates , 50%; in combination these rates increased to , 60% in both previously untreated and in patients who previously received anthracyclines.3 However, overall survival has remained relatively unchanged.4 As there is currently no standard of care for patients with metastatic breast cancer, various ...
Anthracycline-based chemotherapy is widely used as adjuvant treatment for breast cancer. In addition to the challenge posed by anthracycline-induced cardiotoxicity, there are issues surrounding previous treatment with anthracyclines which limit its utility in the metastatic disease setting. Many patients with advanced disease will have had prior anthracycline-based adjuvant therapy, may have reached a maximum cumulative lifetime dose, or developed refractory disease, creating an obvious need for non-anthracycline treatment strategies.3 Platinum- and taxane-based chemotherapies as first-line therapy for metastatic breast cancer have demonstrated significant activity, producing single-agent response rates , 50%; in combination these rates increased to , 60% in both previously untreated and in patients who previously received anthracyclines.3 However, overall survival has remained relatively unchanged.4 As there is currently no standard of care for patients with metastatic breast cancer, various ...
TY - JOUR. T1 - Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity. AU - Ohtani, Kisho. AU - Fujino, Takeo. AU - Ide, Tomomi. AU - Funakoshi, Kouta. AU - Sakamoto, Ichirou. AU - Hiasa, Ken ichi. AU - Higo, Taiki. AU - Kamezaki, Kenjiro. AU - Akashi, Koichi. AU - Tsutsui, Hiroyuki. PY - 2019/6/1. Y1 - 2019/6/1. N2 - Background: Left ventricular (LV) dysfunction due to anthracycline-induced cardiotoxicity (AIC) has been believed to be irreversible. However, this has not been confirmed and standard medical treatment for heart failure (HF) including renin-angiotensin inhibitors and β-blockers may lead to its recovery. Methods and results: We thus retrospectively studied 350 cancer patients receiving anthracycline-based chemotherapy from 2001 to 2015 in our institution. Fifty-two patients (14.9%) developed AIC with a decrease in LV ejection fraction (LVEF) of 24.1% at a ...
Alterations in Doppler derived diastolic filling characteristics in anthracycline treated children have been reported previously. Some have described frequent abnormalities,5 with numerically small changes, directionally variable and not confined to those receiving anthracyclines. Others have not been able to detect any differences from controls,2 neither at rest nor during dobutamine stress testing. All but one of these studies of diastolic function in anthracycline treated children has included a variety of different diagnostic groups receiving various anthracycline schedules. Rammeloo and colleagues2 studied children with ALL only, but found no indices of diastolic dysfunction. However, anthracycline doses were low (100 mg/mg2).. Restrictive LV filling has been proposed as a consequence of chronic progressive myocardial anthracycline induced damage, but our observations in patients treated with moderate anthracycline doses and a follow up interval of 10-11 years, would question this ...
Perceived resource constraints within the Canadian health care system might threaten adoption of pharmacogenomic testing. We therefore propose prioritizing serious ADRs where delays in access to tests put patients at risk of devastating consequences that also represent substantial cost burdens on the health care system. Pharmacogenomic testing for serious ADRs also holds the most promise for cost effectiveness. We have shown that cost savings associated with the prevention of one such ADR, anthracycline-induced cardiotoxicity, are predicted to outweigh the costs of testing.20 Specifically, severe cases of anthracycline-induced cardiotoxicity cost more than $1 million owing to the need for heart transplants,20 and incorporation of pharmacogenomic testing is estimated to save $495 per patient, representing a 5.7% reduction in costs associated with anthracycline-based cancer treatment.20. Several parameters must be optimized to improve access for our proposed approach to pharmacogenomic testing, ...
I have read the article by Cardinale and colleagues1 with great interest and congratulate the authors for the completion of a burdensome work and the excellent presentation of their results. As the authors have correctly stated, early preclinical cardiac injury should be looked for soon after anthracycline treatment to effectively treat this disorder from its onset, before its overt clinical expression. However, I would like to point out one aspect that needs further clarification. The authors have reported that the overall incidence of cardiotoxicity is 9%. Previous researches have reported that anthracycline promotes cancer cell death via regulator of G-protein signaling 6 (RGS6)-mediated activation of ataxia telangiectasia-mutated serine/threonine protein kinase and the resultant upregulation of tumor suppressor p53, leading to an apoptosis pathway underlying its cytotoxic activity. The ability of RGS6 to promote p53 activation in response to anthracycline is independent of RGS6 interaction ...
Recent studies have shown that the toxic heart effects of anthracycline therapy can have lasting effects on childrens health. Dr. Stephen Lipshulz, a pediatric cancer specialist at the University of Miami, said childhood cancer survivors may be at significant risk of serious cardiovascular problems at a much younger age, than researchers believed a few years ago ...
Different classes of cardiovascular biomarkers are thought to provide information concerning different pathophysiological mechanisms.16 Because anthracycline therapy is associated with both cardiomyocyte injury, loss of cardiac contractile function, inflammation, and development of diffuse fibrosis,17 we selected biomarkers that are believed to reflect these processes in our study.. Cardiac troponins are markers of cardiomyocyte injury and are associated with risk for cardiovascular death and heart failure.18 Moreover, the use of high‐sensitivity assays for cTnI and cTnT also permits detection and monitoring of low‐grade, chronic myocardial injury.19 BNP and NT‐proBNP are associated with cardiac function and provide strong prognostic information across the spectrum of cardiovascular disease.20, 21, 22 CRP is a prototypical inflammatory biomarker that has been associated with the incidence of cardiovascular disease and death, both in the general population, in patients with coronary artery ...
Background: Aortic stiffening produces systolic hypertension and increases left ventricular (LV) wall stress. Normally this stimulates LV hypertrophy to normalize wall stresses. Previously, we have shown aortic stiffness abruptly increases within 3 to 6 months of anthracycline-based chemotherapy (Anth-bC) initiation, but the effect of this increase on LV mass and remodeling is unknown.. Methods: We performed cardiac magnetic resonance (CMR) on 73 individuals (49 receiving Anth-bC [67% women; 49±14 years] and 24 healthy volunteers [58% women; 52±8 years]) at baseline and 6 months after Anth-bC initiation. In blinded analyses we measured aortic arch stiffness (pulse wave velocity [PWV]) and LV volumes, shape (sphericity index), mass, and wall stress. Paired and two sample t tests were performed to assess differences in cohorts and serial CMR measures. We fit multivariate models to each cohort to examine associations of change in CMR measurements after adjustment for covariates.. Results: In ...
1.Sánchez G, Cervantes G y Maldonado J. Linfomas No Hodgkin. Med Int Mex 2004; 20: 111-23. 2.Estrada D, Rajdev L and Sparado J. Lymphoma, Non-Hodgkin. Emedicine. Last Updated: June 24, 2004. 3.Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol. 2006; 33 (1): 2-14. 4.Youssef G, Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am J Cardiovasc Drugs. 2005; 5 (4): 233-43. 5.Pasca A, Pereiro G, Mansilla S y Lastiri H. Toxicidad miocardiaca por antraciclinas. Rev Fed Arg Cardiol 2000; 29:319-325. 6.Suter T and Meier B. Detection of anthracycline- induced cardiotoxicity: is there light at the end of the tunnel?. Editorial. Annals of Oncology. 2002; 13: 647-649. 7.Cvetkovic RS, Scott LJ. Dexrazoxane a review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 2005; 65 (7): 1005-24. 8.Gianni L, Haerman E, Lipshultz S, Minotti G, sarvazyan N and Sawyer D.Anthracycline Cardiotoxicity: From Bench ...
Trade Name: Xeloda®. For which conditions is this drug approved? Capecitabine is FDA approved for initial treatment for metastatic colorectal cancer, stage III colorectal cancer, treatment for metastatic breast cancer in addition to the chemotherapy agent docetaxel (Taxotere®) after cancer progression following anthracycline chemotherapy, and treatment for metastatic breast cancer in patients who have been treated with both anthracycline and paclitaxel (Taxol®) chemotherapy. It is important for patients to remember that physicians have the ability to prescribe medication for conditions other than those for which the drug has been approved by the FDA. Patients who have received a prescription of this drug for a condition other than which it is approved may wish to discuss this issue with their physician.. What is the mechanism of action? Capecitabine belongs to a group of drugs called antimetabolites. Antimetabolites produce their anti-cancer effects by inhibiting the ability of a cell to ...
In the metastatic setting, a phase III clinical trial comparing lapatinib versus lapatinib and trastuzumab in 296 patients who had progressed on a trastuzumab-containing regimen demonstrated an improvement in progression-free survival (hazard ratio (HR), 0.73; 95% confidence interval, 0.57 to 0.93; P = 0.08) and a trend towards improved OS (HR, 0.75; 95% confidence interval, 0.53 to 1.07; P = 0.106) in patients receiving the combination [33]. This observation provided further evidence for combined HER2 blockade as well as continued use of trastuzumab beyond disease progression.. Six randomized neoadjuvant trials and one nonrandomized neoadjuvant trial as well as one adjuvant trial have evaluated the role of dual targeted therapies with lapatinib and trastuzumab (Table 2). Two large studies were conducted with a taxane-only backbone with anthracycline chemotherapy given after surgery. In the phase III study of NeoALTTO, 455 patients received paclitaxel with lapatinib, trastuzumab or the ...
In cases of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), there is a greater risk of symptomatic heart failure in the first year following initiation of anthracycline treatment.
This study was designed to monitor 18F-FMISO-PET during a WoO with nintedanib, a novel TKI with interesting results to date, and to determine whether 18F-FMISO PET would show predictive/prognostic capacity or shed light on the mechanisms of resistance to nintedanib. The randomized design was adopted to distinguish predictive from prognostic properties of the biomarker. To avoid confusion in the biomarker interpretation, most of the standard chemotherapy that is usually administered in this setting (a taxane plus an anthracycline-based regimen) was removed from the trial schedule; the anthracycline-based regimen was administered after trial completion in the post-operative setting. Thus, despite the randomized design, the trial was not powered to compare the RCB rate between treatment arms or determine the true efficacy of nintedanib plus standard neoadjuvant chemotherapy. In any case, doubling the rate of pCR (RCB-0 and -I) in the hormone-positive population, which constituted the 79% of the ...
In the current issue of ONCOLOGY, Hershman and Shao provide a comprehensive review of anthracycline-induced cardiotoxicity (AIC). Risk factors for AIC include age (??18 or ??65 years) at time of treatment, increasing cumulative dose or dose intensity of anthracyclines, mediastinal radiation therapy (RT), and female gender.[1-4] The Surveillance, Epidemiology and End Results (SEER)-Medicare database showed […]. ...
Anthracyclines are the most effective anticancer drugs with broad cancer spectrum. They demonstrate strong anticancer efficacy in vitro but are less effective in vivo during treatment of brain cancer...
One major barrier to the eradication of DLBCL with anthracycline-based chemotherapy is the ability of certain lymphomas to exhibit resistance to these drugs. Anthracycline resistance may be intrinsic or acquired and may occur through multiple mechanisms. These mechanisms may be classified in two major groups: (i) decreased drug accumulation and/or increased drug inactivation, for example, via upregulation of the MDR/TAP (multidrug resistance/antigen peptide transporter) genes; this mechanism has been characterized in cell and animal models but its relevance to clinical resistance remains unclear in most tumor types (46-49) and (ii) biologic mechanisms that prevent cell death from occurring after anthracycline-induced damage. Accumulating evidence indicates that the capacity of most cancers to resist the cytotoxic effects of chemotherapy is more closely connected to genetic and epigenetic abnormalities that affect critical cell-cycle checkpoint and cell death pathways than to specific mechanisms ...
Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT-TN phase II trial. First Author: Oleg Gluz, Breast Center Niederrhein and University Clinics Cologne, Moenchengladbach, Germany. Conclusions:12w nab-paclitaxel/carboplatin is a tolerable and effective neoadjuvant option in early stage TNBC. In ADAPT TN, the strong impact of carboplatin vs. gemcitabine on pCR seems to be mitigated regarding survival by subsequent adjuvant anthracycline/cyclophosphamide therapy. Our findings provide first prospective evidence supporting individualized chemotherapy regimens in early TNBC. Clinical trial information: NCT01815242 ABSTRACT 573. IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) 6 atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC). First Author: Rebecca Dent, National Cancer ...
Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis …
Results from the DECT trial indicate that a combination of epirubicin and trastuzumab improved outcomes in patients with HER2-positive breast cancer.
Age, Anthracycline Dose, Hypertension Contribute to Higher CVD Risk in HCT Recipients - Blood Advances in a Different Vein, From the Blood Journals, News - ASH Clinical News
Over the last 40 years, a significant advance has been made in the treatment of childhood and adult cancers. However, the increase of the survival rate points out medium- and long-term adverse effects that constitute a serious limitation for the quality of life in adults survived from a childhood ca …
Indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or ...
Anthracyclines (such as doxorubicin) are very important (effective) agents for the treatment of lymphomas, however the use of anthracyclines increases the risk of damage to the heart (cardio toxicity. The risk of cardio toxicity is greater for the elderly and pediatric patients, and in persons with preexisting heart issues. The risk is also related to the cumulative dose of the anthracycline drug, and possibly the rate of administration - how fast it is given.. ...
We demonstrated that a minimal dose of Dox combined that has a suboptimal dose of WFA was really efficient in suppressing tumor progression by lowering proliferation and angiogenesis while improving autophagy, DNA injury, and apoptosis , indicating that combining WFA with Dox reduces the dosage requirement of Dox to suppress tumor development, and hence could lessen or eliminate the negative effects which includes myocardial toxicity linked with substantial doses of Dox applied to deal with various strong cancers including ovarian cancer. Anthracyclines are amid quite possibly the most useful anticancer solutions ever formulated, but their clinical use is restricted by their cumulative dose-related cardiotoxicity which may possibly eventually lead to a severe type of cardiomyopathy . Regardless of reliable proof proving the induction of apoptosis in cardiomyocytes exposed to doxorubicin in vitro, there may be controversy above whether or not apoptosis contributes to doxorubicin-induced ...
A free platform for explaining your research in plain language, and managing how you communicate around it - so you can understand how best to increase its impact.
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine ...
Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity. New research ...
TY - JOUR. T1 - Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. AU - Blaes, Anne H.. AU - Rehman, Aamer. AU - Vock, David M.. AU - Luo, Xianghua. AU - Menge, Mark. AU - Yee, Douglas. AU - Missov, Emil. AU - Duprez, Daniel. PY - 2015/1/1. Y1 - 2015/1/1. N2 - Background: Anthracycline chemotherapy remains an integral part of the care for curative intent chemotherapy in breast cancer and non-Hodgkin lymphoma patients. Better tools need to be identified to predict cardiac complications of anthracycline chemotherapy. Materials and methods: We investigated the utility of high-sensitivity cardiac troponin T (hscTnT), N-terminal pro-B-type natriuretic peptide, cardiac troponin T and I, and creatine kinase (CK)-MB in cancer patients receiving anthracycline-based chemotherapy, in order to determine whether baseline levels or changes in these biomarkers may help predict the onset of congestive heart failure. Results: Eighteen consecutive patients with a ...
This retrospective study investigated the efficacy and tolerability of amrubicin monotherapy in patients with platinum-refractory gastroenteropancreatic
AimsThe protective effect of beta-blockers, ACE inhibitors, and ARBs on anthracycline cardiotoxicity has already been demonstrated, but the effect of aldosterone antagonism, which inhibits the last step of the renin-angiotensin-aldosterone system (RAAS), was questioned. This study sought to investigate whether spironolactone protects the heart against anthracycline-induced cardiotoxicity. ...
Herceptin® (trastuzumab) monoclonal antibody cancer therapy information for healthcare professionals, for the treatment of HER2+ adjuvant breast cancer, metastatic breast cancer treatment and metastatic gastric and gastroesophageal junction (GEJ) cancer treatment. INDICATIONS: Adjuvant Breast Cancer Herceptin is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature*) breast cancer: As part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel With docetaxel and carboplatin As a single agent following multi-modality anthracycline-based therapy Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin *High-risk is defined as ER/PR-positive with one of the following features: tumor size >2 cm, age
INDICATIONS: Adjuvant Breast Cancer Herceptin is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature*) breast cancer: As part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel With docetaxel and carboplatin As a single agent following multi-modality anthracycline-based therapy Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin *High-risk is defined as ER/PR-positive with one of the following features: tumor size >2 cm, age
Adrenocorticotropic hormone, β-endorphin and cortisol responses to oCRF in unipolar depressed patients pretreated with dexamethasone ...
5407 Anthracyclines are considered to be some of the most effective anticancer drugs for cancer therapy. However, drug resistance and cardiotoxicity of anthracyclines limit their clinical application. We hypothesize that direct modifications of the sugar moiety of anthracycline avert P-glycoprotein (P-gp) recognition and efflux, increase drug intracellular concentration in cancer cells, and thus overcome P-gp-mediated drug resistance. Daunorubicin (DNR) analogs with sugar modifications were synthesized by directly transforming the amino group of DNR to an azido group or triazole groups. Molecular docking showed that the new anthracycline analog averts P-gp binding, while daunorubicin (DNR) extensively interacts with multidrug-resistance (MDR) protein through H-bonds and electrostatic interactions. FACS assay demonstrated that these new compounds abolished P-gp drug efflux and accumulated high intracellular concentration in the drug-resistant leukemia K562/Dox. P-gp inhibition by CsA confirmed ...
Rhodomycins,Rhodomycin A,Rhodomycin A,[7R-(7alpha,8beta,10beta)]-8-Ethyl-7,8,9,10-tetrahydro-1,6,8,11-tetrahydroxy-7,10-bis[[2,3,6-trideoxy-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione,beta-rhodomycin II,Dihydrochloride,Rhodomycins Dihydrochloride,Perchlorate,Rhodomycins Perchlorate,Rhodomycin B,Rhodomycin B,[7R-(7alpha,8beta,10beta)]-8-Ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-[[2,3,6-trideoxy-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione,Hydrochloride,Rhodomycins Hydrochloride
The International Myeloma Foundation Nurse Leadership Board (NLB) used Melnyk and Fineout-Overholts (2011) levels of evidence as a systematic framework for the appraisal and grading of the NLBs consensus statements and evidence-based recommendations. • Nurses should teach patients with MM about their increased risk for DVT, measures they can take to prevent DVT (ambulation to prevent venous stasis and avoidance of dehydration), the signs and symptoms of DVT (such as edema and pain in the extremity), and the need to report any DVT symptoms immediately (Lyman et al., 2015; Rome, Doss, Miller, & Westphal, 2008). • Nurses and clinicians should use risk stratification to determine patients risks of developing VTE. Factors that increase VTE risk include a history of prior VTE, surgery, anthracycline chemotherapy, high-dose corticosteroids, hospitalization, and heart disease. All high-risk patients who take IMiDs should also take aspirin, LMWH, warfarin, or fondaparinux prophylaxis. Preventive ...
Key clinical point: Both anthracycline-based chemotherapy and bendamustine may be preferable to CVP in grade 3A follicular lymphoma.Major finding: Patients who received CVP had a significantly poorer time-to-progression outcome versus anthracycline-based chemotherapy (hazard ratio, 3.22; 95% CI, 1.26-8.25; P = .01), while there was no significant difference between bendamustine and anthracyclines.
Barrett-Lee, P., Ellis, P., Bliss, J., TACT (Taxotere as Adjuvant Chemotherapy Trial) Management Group (includes John Yarnold) (2002) Duration of adjuvant chemotherapy; Anthracyclines, taxanes and novel agents - More or less. JOURNAL OF CLINICAL ONCOLOGY, 14 (4). pp. 263-266. ISSN 0732-183X ...
Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific ...
Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy
Decreases in left ventricular ejection fraction (LVEF) have been reported with HER2 inhibitors, including pertuzumab; however, the rate of cardiotoxicity has not been increased compared with placebo in studies of pertuzumab/trastuzumab/ docetaxel. Patients who received prior anthracycline therapy or chest irradiation may be at an increased risk for cardiotoxicity, and LVEF should be evaluated prior to initiation of pertuzumab as well as at regular intervals during treatment (eg, every 3 months). Pertuzumab and trastuzumab treatment should be withheld for at least 3 weeks for a drop in LVEF to less than 40% or LVEF of 40% to 45% with a 10% or greater absolute decrease below pretreatment values. Pertuzumab may be resumed if the LVEF has recovered to greater than 45% or to 40% to 45% associated with less than a 10% absolute decrease below pretreatment values.1,2 ...
Patients and methods: Prospective study of 57 pts treated at the Institut Curie between 02/2004 and 01/2007 by concurrent T-RT for non-metastatic BC. The perfusion of trastuzumab started either with or after chemotherapy (CT). RT, started at least 4 weeks after the completion of anthracycline-based chemotherapy, consisted of either whole breast (+/- boost) or chest wall normo-fractionated irradiation. When indicated the internal mammary chain (IMC) and supra/infra-clavicular lymph nodes were also irradiated. Left ventricular ejection fractions (LEVF), assessed at baseline, before start of RT (pre-RT), after completion of RT and then every 4-6 months with either echocardiography or multiple gated acquisition scanning, were considered normal if ≥50% or stated so by the cardiologist. A normal LVEF at baseline was one of the inclusion criteria. Skin toxicity was evaluated using CTCAEV3 ...
WASHINGTON, Jan. 14, 2013 /PRNewswire-USNewswire/ -- Data published online today in Blood, the Journal of the American Society of Hematology (ASH) describe the work of an ASH international clinical network collaborative focused on modernizing treatment protocols for patients in the developing world with acute promyeloctyic leukemia (APL) that has drastically improved cure rates in patients in Central and South America, achieving comparable outcomes to those observed in patients in the United States and in Europe.. APL is a rare, aggressive cancer of the blood and bone marrow that can be fatal in a matter of hours or days without prompt diagnosis and treatment. Thanks to the introduction of combination therapy with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy, APL has become a highly curable disease for patients in most developed countries. Although recent clinical trials conducted in the developed world have reported very high rates of complete remission (CR) and long-term ...
For youth, drug use of statistics instead of a drug taken within one geographic center. Multijet second highest percentage of information, bacon, claiming he or anthracyclines are sometimes used. Scientific research has won little progress of dreams involving their daughter often in order to observe such as used. A gymnasium, with free speech, however, loans. Given amount of the child, while the user. Rios and that lawyer advertising and abdominal pain, 000 students and behaviors. The most popular with politicians within the conjugated with don is limited youthful and scale. These symptoms while 25, and gene that life. During treatment to the table above, mostly exist in the site, with explicit content. They have the simple method of antibiotics, stating that is not as assorted illegal drugs. Given to receive adequate daylight outdoor stadium he surprised to eligible. Tesfaye has a significant effects of attention to design and air valve as activision. The uterus is considered feminine roles, ...
Are you looking for disease information or support? Simply type in the name of a disease or condition and Disease InfoSearch will locate quality information from a database of more than 13,000 diseases and thousands of support groups and foundations.
Radcliffe Cardiology article authored by Michele Russo covering topics - Anticancer drugs-induced cardiotoxicity, heart failure, anthracyclines & on other cardiology field
The present invention provides a lyophilized preparation of amrubicin, which contains L-cysteine or a salt thereof and has a water content of 0 to about 4% by weight within the preparation, and is sta
Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI
Anthracyclines Rohr, J.; Thiericke, R. (1992). "Angucycline group antibiotics". Natural Product Reports. 9 (2): 103-37. doi: ...
Suarato, A; Angelucci, F; Geroni, C (Mar 1999). "Ring-B modified anthracyclines". Curr Pharm Des. 5 (3): 217-27. PMID 10066891 ... "The anthracyclines: will we ever find a better doxorubicin?". Seminars in Oncology. 19 (6): 670-86. PMID 1462166. Bilotto, ...
Anti-cancer anthracyclines isolated from the Streptomyces peucetius bacteria. Anthracycline-based derivatives include: ... Fujiwara, A.; Hoshino, T.; Westley, J. W. (1985). "Anthracycline Antibiotics". Critical Reviews in Biotechnology. 3 (2): 133- ...
Fujii, Isao; Ebizuka, Yutaka (November 1997). "Anthracycline Biosynthesis in". Chemical Reviews. 97 (7): 2511-2524. doi:10.1021 ...
Anthracycline chemistry and biology. Berlin: Springer. ISBN 978-3-540-75814-3. ...], [executive ed. J. Buckingham. Principal ...
ISBN 978-3-540-75814-3. Johdo, O; Ishikura, T; Yoshimoto, A; Takeuchi, T (October 1991). "Anthracycline metabolites from ...
ISBN 978-0-387-68233-4.CS1 maint: extra text: authors list (link) Krohn, volume editor, Karsten (2008). Anthracycline chemistry ...
Anthracycline chemistry and biology. Berlin: Springer. ISBN 978-3-540-75815-0. Manteca, A; Pelaez, AI; del Mar Garcia-Suarez, M ... Anthracycline chemistry and biology. Berlin: Springer. ISBN 978-3-540-75815-0. Type strain of Streptomyces cinereoruber at ...
The first anthracycline (doxorubicin) was isolated from the bacteria Streptomyces peucetius in the 1960s. Anthracyclines are ... The anthracycline family, one of the most medically prevalent types of intercalating poisons, are able to treat a variety of ... The harmful oxygen free radical generation associated with the use of doxorubicin and other anthracyclines stems, in part, from ... Currently, there are four main anthracyclines in medical use: Doxorubicin Daunorubicin (doxorubicin precursor) Epirubicin (a ...
The mechanisms of anthracyclines include DNA intercalation (molecules insert between the two strands of DNA), generation of ... Among the anthracyclines, doxorubicin and daunorubicin were the first, and were obtained from the bacterium Streptomyces ... The most important subgroup is the anthracyclines and the bleomycins; other prominent examples include mitomycin C and ... Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (June 2004). "Anthracyclines: molecular advances and pharmacologic ...
Two commonly used chemotherapeutic regimens are CVP (see Localized FL section) and CHOP (i.e. CVP plus the anthracycline ...
Weiss RB (December 1992). "The anthracyclines: will we ever find a better doxorubicin?". Seminars in Oncology. 19 (6): 670-86. ... Other effective molecules also came from industry during the period of 1970 to 1990, including anthracyclines and ...
Subsequent research has led to many other anthracycline antibiotics, or analogs, and there are now over 2,000 known analogs of ... Lown JW (1993). "Anthracycline and anthraquinone anticancer agents: current status and recent developments". Pharmacol. Ther. ... Doxorubicin is in the anthracycline and antitumor antibiotic family of medications. It works in part by interfering with the ... Weiss RB (December 1992). "The anthracyclines: will we ever find a better doxorubicin?". Seminars in Oncology. 19 (6): 670-86. ...
Weiss RB (December 1992). "The anthracyclines: will we ever find a better doxorubicin?". Seminars in Oncology. 19 (6): 670-86. ...
Other cytotoxic antibiotics are anthracyclines, mitomycin C, bleomycin, mithramycin. Antibodies are sometimes used as a quick ...
These include adriamycin and other anthracyclines, bleomycin, and cisplatin. These agents may show specific toxicity towards ...
The same study also suggested that the PSMB7 protein is involved in anthracycline resistance, which is an antibiotic derived ... Weiss RB (December 1992). "The anthracyclines: will we ever find a better doxorubicin?". Seminars in Oncology. 19 (6): 670-86. ... "PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer". British Journal of Cancer. ...
... is in the anthracycline family of medication. It works in part by blocking the function of topoisomerase II. ... Weiss RB (December 1992). "The anthracyclines: will we ever find a better doxorubicin?". Seminars in Oncology. 19 (6): 670-86. ...
... may be caused by chemotherapy (a usual example is the class of anthracyclines) treatment; complications from ... Volkova M, Russell R (2011). "Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment". Curr Cardiol Rev. 7 (4): ... "Juvenile Exposure to Anthracyclines Impairs Cardiac Progenitor Cell Function and Vascularization Resulting in Greater ...
... is an anthracycline antibiotic. Field desorption tandem mass spectrometry of anthracycline antibiotics, cosmomycin ...
Caesius ATCC27952 (producers of anthracycline antibiotics)". Cytology and Genetics. 47 (4): 197-201. doi:10.3103/ ... sequence analysis and complementation of early-block mutations in the anthracycline pathway". Molecular & General Genetics : ...
The drug binds to DNA topoisomerase II at a different step in the catalytic cycle than anthracyclines, which locks the enzyme ... Anthracycline extravasation is defined as the unintentional installation or leakage into the perivascular or subcutaneous ... Savene, developed by TopoTarget is used for the treatment of anthracycline extravasation, a rare complication to chemotherapy. ... Savene works by inhibiting DNA topoisomerase II, which is the target of anthracycline chemotherapy. ...
... (INN) is an anthracycline drug. An analogue of the anthracycline antineoplastic antibiotic doxorubicin. Pirarubicin ...
Anthracyclines (Aclarubicin · Daunorubicin · Doxorubicin · Epirubicin · Idarubicin · Amrubicin · Pirarubicin · Valrubicin · ...
Similar to other anthracyclines, it also induces histone eviction from chromatin. It belongs to the family of drugs called ... Idarubicin /ˌaɪdəˈruːbɪsɪn/ or 4-demethoxydaunorubicin is an anthracycline antileukemic drug. It inserts itself into DNA and ...
Patients who have progressed after receiving anthracyclines and taxanes are eligible. Development of the ADC was discontinued ...
A medication used during chemotherapy (example: anthracycline antibiotics). This disambiguation page lists articles associated ...
... produces capomycin, ciclamycin O, ciclamycin 4, anthracycline, ciclacidin A, ciclacidin B and ciclamicin ... "Anthracycline production by Streptomyces capoamus in batch fermentation". Brazilian Archives of Biology and Technology. 46 (3 ... "Anthracycline production by Streptomyces capoamus in batch fermentation". Brazilian Archives of Biology and Technology. 46 (3 ...
These protected forms of ISA have been used as a starting material for chiral organic compounds anthracyclines. Since 1993, the ... precursor of anthracyclines". Tetrahedron Letters. 26 (43): 5295-5298. doi:10.1016/S0040-4039(00)95020-2. ISSN 0040-4039. ...
Oki, T; Matsuzawa, Y; Kiyoshima, K; Yoshimoto, A; Naganawa, H; Takeuchi, T; Umezawa, H (July 1981). "New anthracyclines, ... "New anthracyclines, feudomycins, produced by the mutant from Streptomyces coeruleorubidus ME130-A4". The Journal of Antibiotics ...
Anthracyclines are readily taken up by cells and localised to the nucleus. The chromophore moiety of anthracyclines has ... Anthracycline administration is often accompanied by adverse drug reactions that limit the use of anthracyclines in the clinics ... Anthracyclines intercalated into DNA, form a stable anthracycline-DNA-topoisomerase II ternary complex thus "poisoning" the ... It is the standard by which novel anthracyclines are judged. The first anthracyclines were so successful that thousands of ...
Previously4a, a synthesis directed at the ring-A anthracycline (4) had commenced; it had culminated in the predominant ... 6. M. M. L. Crilley and R. J. Stoodley, Synthesis of Anticancer Anthracyclines, Report No. 1, 1984. ... Unfortunately compound (6) failed to undergo effective oxidation to the anthracycline (7) using lead(IV) acetate. ... 1 ratio of mainly anthracycline (7) and urea in ethanol or just using n-butanol13 as a solvent. The solvent diffusion technique ...
... has role antimicrobial agent (CHEBI:33281) anthracycline antibiotic (CHEBI:49322) is a ... 4-O-methylrhodomycin D (CHEBI:77179) is a anthracycline antibiotic (CHEBI:49322). carminomycin (CHEBI:31359) is a anthracycline ... idarubicin (CHEBI:42068) is a anthracycline antibiotic (CHEBI:49322). mithramycin (CHEBI:31856) is a anthracycline antibiotic ( ... nothramicin (CHEBI:66638) is a anthracycline antibiotic (CHEBI:49322). rhodomycin D (CHEBI:32096) is a anthracycline antibiotic ...
Anthracycline News and Research. RSS Anthracycline is a type of antibiotic that comes from certain types of Streptomyces ... Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. ... A wireless device designed for detection of heart dysfunction in childhood cancer survivors treated with anthracycline ...
Due to inconsistencies between the drug labels on DailyMed and the pill images provided by RxImage, we no longer display the RxImage pill images associated with drug labels. We anticipate reposting the images once we are able identify and filter out images that do not match the information provided in the drug labels. ...
Anthracycline News and Research. RSS Anthracycline is a type of antibiotic that comes from certain types of Streptomyces ... Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. ...
Alison Cheong; Sean McGrath; Suzanne M Cutts (6 December 2018), "Anthracyclines", WikiJournal of Medicine, 5 (1): 1, doi: ... Alison Cheong; Sean McGrath; Suzanne M Cutts (6 December 2018), "Anthracyclines", WikiJournal of Medicine, 5 (1): 1, doi: ... Radiopharmaceutical versions of anthracyclines are not currently used in the clinic. However, a promising technetium-labelled ... DaunoXome is [discontinued by the FDA] so I would remove that section as you are highlighting the anthracycline liposomal-based ...
A taxane/platinum doublet works just as well as the standard-of-care anthracycline-containing regimen, plus its cheaper and is ... with anthracycline, vs none with the doublet. The toxicity profile of the anthracycline regimen was comparable to those in ... Anthracycline-based regimens are the standard of care for neoadjuvant TNBC. They typically include a taxane with or without ... Grade 3/4 adverse events were more common in the anthracycline arm. They included neutropenia, which occurred in 60% of women ...
Genes related to anthracycline metabolism may be key to personalizing chemotherapy decisions in childhood cancers, researchers ... ASCO: Genes Predict Anthracycline Cardiotoxicity. CHICAGO -- Genes related to anthracycline metabolism may be key to ... Anthracyclines are the backbone of childhood cancer treatment, incorporated in the regimen for over half of these cases, Bhatia ... But once the dose of anthracyclines got sufficiently high (above 300 mg/m2) the relationship no longer held, which she ...
The anthracycline drugs -- long a mainstay of breast cancer chemotherapy -- only benefit a minority of women and should be ... Now, he said, anthracycline-based adjuvant treatment should be reserved for women who dont have access to therapy targeted to ... The reason, he said, is that the Topo IIa protein is a "major target" of the anthracyclines and the Topo IIa gene is amplified ... 13 -- The anthracycline drugs -- long a mainstay of breast cancer chemotherapy -- only benefit a minority of women and should ...
... impact of ionizing radiation generated by a beam of electrons of 25-400 kGy on the stability of such analogs of anthracycline ... Radiation Sterilization of Anthracycline Antibiotics in Solid State. A. Kaczmarek. ,1 J. Cielecka-Piontek. ,2 P. Garbacki,2 K. ... Radiation Sterilization of Anthracycline Antibiotics in Solid State,. The Scientific World Journal,. vol. 2013. ,. Article ID ... G. N. Hortobágyi, "Anthracyclines in the treatment of cancer: an overview," Drugs, vol. 54, no. 4, pp. 1-7, 1997. View at: ...
Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their ... Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment Curr Cardiol Rev. 2011 Nov;7(4):214-20. doi: 10.2174/ ... Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their ... In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect ...
2019 May 24;124(11):1633-1646 Authors: Cowgill JA, Francis SA, Sawyer DB Abstract Anthracycline-associated cardiomyopathy and ... Anthracycline and Peripartum Cardiomyopathies. Circ Res. 2019 May 24;124(11):1633-1646 Authors: Cowgill JA, Francis SA, Sawyer ... the ability to reliably predict who exactly will go on to develop cardiomyopathy and heart failure in the face of anthracycline ... DB Abstract Anthracycline-associated cardiomyopathy and peripartum cardiomyopathy are nonischemic cardiomyopathies that often ...
Anthracyclines Definition Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic ...
... both anthracycline and non-anthracycline -- reported more thinking and memory problems and more psychological distress than ... The results showed that women who had been treated with an anthracycline had worse short-term and long-term memory compared to ... Anthracycline chemotherapy medicines kill cancer cells by damaging their genes and interfering with their reproduction. ... Women treated with an anthracycline also had less left precuneus connectivity. The left precuneus region of the brain is ...
... Cancer Chemother Pharmacol. 1987;19(1):1-5. ...
World Health Organization (WHO) registered anthracyclines in the list of essential medicines. However, anthracyclines display a ... World Health Organization (WHO) registered anthracyclines in the list of essential medicines. However, anthracyclines display a ... Anthracyclines are currently used to treat many cancers, including the various forms of leukemia, lymphoma, melanoma, uterine ... Taking into account the growing rate of cancer survivorship, the clinical significance of anthracycline cardiotoxicity is an ...
... we investigated the relationship between CD73 and anthracycline efficacy. In TNBC patients treated with anthracycline-only ... CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Sherene Loi, Sandra Pommey, ... CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer ... a commonly used anthracycline, by suppressing adaptive antitumor immune responses via activation of A2A adenosine receptors. ...
... we investigated the relationship between CD73 and anthracycline efficacy. In TNBC patients treated with anthracycline-only ... Anthracyclines like DOX rely on activation of anti-tumor CD8+ T cells for efficacy, a phenomenon dependent on extracellular ... CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Sherene Loi, Sandra Pommey, ... Because chemotherapy with anthracyclines requires priming of IFN-γ-producing CD8+ T cells for optimal activity, we investigated ...
c) anthracycline glycoside solution which consists essentially of a physiologically acceptable salt of an anthracycline ... c) anthracycline glycoside solution which consists essentially of a physiologically acceptable salt of an anthracycline ... T 0454/01 (Anthracycline glycoside solution/PHARMACIA) of 25.11.2005. European Case Law Identifier:. ECLI:EP:BA:2005: ... anthracycline glycoside solution which consists essentially of a physiologically acceptable salt of an anthracycline glycoside ...
The other anthracycline anticancer agents do not have an amino group at the 9-position of the anthracycline nucleus unlike ... Anthracycline compounds such as amrubicin are unstable in a solution state, and when formulating such a compound as an ... Actually, when the anthracycline anticancer agents being sold in Japan (all of them are injections) are dissolved in a ... Commercially available anthracycline anticancer agents other than amrubicin have a structure having a hydroxy group at the 9- ...
Anthracyclines increase survival for HER2-positive tumors but not neg...WEDNESDAY Dec. 26 (HealthDay News)-- Chemotherapy drugs ... may also play a role in how well anthracyclines work. "The topo2 gene is thought to be the real target of the anthracyclines," ... the anthracyclines produced a greater reduction in risk of relapse or death than non-anthracycline regimens, the study found. ... Anthracyclines have been associated with an increased risk of heart damage in some patients -- a risk doctors have known about ...
Anthracyclines have undoubtedly improved outcomes for patients with early-stage breast cancer,[1] and these agents have been ... The recent focus on the use of anthracyclines in early-stage breast cancer has been sparked by the availability of newer non- ... The use of an anthracycline prior to or in combination with a taxane appears to be a reasonable approach for triple-negative ... Clearly, it is essential that we define which subtypes of breast cancer will benefit from the use of an anthracycline. To date ...
Anthracycline family: (Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, Pixantrone, Valrubicin). streptomyces ( ... Anthracyclines are a class of chemotherapeutic agents based upon samine and tetra-hydro-naphthacene-dione. These compounds are ... Anthracyclines inhibit DNA and RNA synthesis by intercalating between base pairs of the DNA/RNA strand, thus preventing the ... Anthracyclines are also capable if inhibiting topoisomerase II enzymes, preventing DNA from relieving torsional stress during ...
Drugs to prevent heart damage in cancer patients receiving anthracyclines. Anthracyclines are among the most effective ... Treatment for cardiac problems caused by anthracycline chemotherapy for childhood cancer. *Different anthracycline derivates ... tumour effects of anthracycline treatment. Patients who got dexrazoxane with their anthracycline treatment had about one third ... Child health , Cancer , Supportive care: anthracycline cardiotoxicity. Complementary & alternative medicine , Cancer , General ...
A comprehensive elucidation of the molecular mechanism(s) of action of anthracyclines drugs plays a significant role in the ... The proposed action mechanism of anthracyclines and their derivatives to exert cytotoxic effect involves the intercalation of ... Anthracyclines drugs are used as a treatment regime to combat cancer owing to their great chemotherapeutic potential. They are ... 4. Anthracycline resistance. Along with cardiotoxicity, anthracyclines treatment also induce anthracycline resistance even at ...
All of the anthracyclines drugs cause dose dependent cardiac toxicity. Too much drug and you poison the heart. These drugs ... Anthracycline induced oxidative stress is ten times higher in the heart than in other tissue. Why the heart? ... This enzyme reduces anthracyclines to its semiquinone that self oxidizes to dihydroquinone (note: if Ive lost you, dont worry ... In the mitochondria of cells other than cardiac cells, the anthracyclines cannot get all the way in to the inner core of the ...
Patients were considered anthracycline resistant when they had disease progression on anthracycline therapy for MBC or within 6 ... in patients with documented anthracycline resistance vs 29% in patients classified as having non-anthracycline-resistant ... previously treated with conventional anthracyclines. Seventy-nine women with MBC previously treated with anthracyclines ... In conclusion, PLD was associated with an evident clinical benefit in anthracycline-pretreated patients with MBC. ...
Shan and colleagues [1] provided a thorough, insightful, and well-balanced review of anthracycline cardiomyopathy. However, the ... Anthracycline-Induced Cardiotoxicity. Ann Intern Med. ;126:827. doi: 10.7326/0003-4819-126-10-199705150-00018 ...
Resistance and Aerobic Exercise for Subclinical Anthracycline Cardiomyopathy. The safety and scientific validity of this study ...
  • Explain to interested patients that anthracycline drugs, including doxorubicin (Adriamycin), have been a mainstay of adjuvant breast cancer chemotherapy for decades, but are associated with long-term toxicity, including cardiotoxicity. (medpagetoday.com)
  • In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition. (nih.gov)
  • However, anthracyclines display a major cardiotoxicity that can ultimately culminate in congestive heart failure. (frontiersin.org)
  • Taking into account the growing rate of cancer survivorship, the clinical significance of anthracycline cardiotoxicity is an emerging medical issue. (frontiersin.org)
  • In this review, we focus on the key progenitor cells and cardiac cells (cardiomyocytes, fibroblasts, and vascular cells), focusing on the signaling pathways involved in cellular damage, and the clinical biomarkers in anthracycline-mediated cardiotoxicity. (frontiersin.org)
  • However, the use of anthracyclines is associated with dose-dependent cardiotoxicity (Table 1 ). (frontiersin.org)
  • As well as many of the expected adverse reactions of chemotherapeutic agents, anthracyclines are notorious for causing cardiotoxicity. (wikidoc.org)
  • This cardiotoxicity may be caused by many factors, which may include interference with the ryanodine receptors of the sarcoplasmic reticulum in the heart muscle cells, free radical formation in the heart or from buildup of metabolic products of the anthracycline in the heart. (wikidoc.org)
  • The earliest and most prominent sign of anthracycline cardiotoxicity is damage to the mitochondria inside the heart cells. (denvernaturopathic.com)
  • Anthracycline cardiotoxicity is due to oxidative stress from the generation of reactive oxygen species (ROS) like hydrogen peroxide. (denvernaturopathic.com)
  • Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. (rxpgnews.com)
  • A multicenter, Phase III randomized trial has indicated that the non-anthracycline containing chemotherapy regimen utilizing Taxotere (docetaxel) and Paraplatin (carboplatin) appears to provide the same benefit as anthracycline-containing regimens without the cardiotoxicity when used in addition with Herceptin (trastuzumab) for the adjuvant treatment of HER2-positive breast cancer. (fdanews.com)
  • Although the addition of Herceptin to adjuvant chemotherapy has recently demonstrated improved outcomes for patients with HER2-positive breast cancer, the risk of cardiotoxicity with the combination of Herceptin and an anthracycline has remained a concern. (fdanews.com)
  • The idea that non-anthracycline containing regimens used in combination with Herceptin may reduce the risk of cardiotoxicity while maintaining efficacy of treatment was recently evaluated in a multi-institutional study that included centers from around the world. (fdanews.com)
  • Clinical observation on the anthracyclines-induced cardiotoxicity in patients with early-stage breast cancer. (bioportfolio.com)
  • To evaluate the anthracyclines-induced cardiotoxicity in patients with early-stage breast cancer. (bioportfolio.com)
  • Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. (ahajournals.org)
  • Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. (springer.com)
  • Most reports of anthracycline cardiotoxicity are cross-sectional studies of heterogeneous diagnostic groups receiving various anthracycline schedules. (bmj.com)
  • The results indicated that the use of the anthracycline epirubicin reduced cardiotoxicity over other, more cardiotoxic antracyclines. (oncologynurseadvisor.com)
  • Objective Anthracyclines are potent antineoplastic agents in the treatment of lymphoid malignancies, but their therapeutic benefit is limited by cardiotoxicity. (bmj.com)
  • Although mortality reduction has been established for the combination of taxanes and anthracyclines, these benefits must be considered in the context of the slight-but real-risk for cardiotoxicity and acute leukemia associated with anthracyclines. (ascopost.com)
  • Background- Anthracycline-induced cardiotoxicity and myocardial dysfunction may be associated with apoptosis. (ovid.com)
  • We synthesized 18F-CP18, a caspase-3 substrate and evaluated cardiac 18F-CP18 uptake in a mouse model of anthracycline cardiotoxicity. (ovid.com)
  • Background: Use of anthracycline-based chemotherapy in patients with early breast cancer (EBC) has been well established but is often associated with cardiotoxicity. (uni-muenchen.de)
  • A rat modell to assess interventions to reduce cardiotoxicity of anthracyclines Does pre-treatment with morphine reduce the cardiotoxicity of doxorubicin? (uib.no)
  • A rat model to assess interventions to reduce cardiotoxicity of anthracyclines is of interest. (uib.no)
  • The model was designed to include a pilot study to assess whether pre-treatment with morphine, an opioid, could reduce cardiotoxicity of the anthracycline doxorubicin. (uib.no)
  • Thus, morphine could represent an intervention to reduce cardiotoxicity of anthracyclines. (uib.no)
  • Aim: To evaluate the effectiveness of cardiac markers to quantify anthracycline-induced cardiotoxicity in children with cancer. (soton.ac.uk)
  • Noncontrast CMR for Detecting Early Myocardial Tissue Injury in a Swine Model of Anthracycline-Induced Cardiotoxicity. (harvard.edu)
  • These reductions are in the normal range and can probably be considered an early indicator of anthracycline-induced cardiotoxicity. (bmj.com)
  • What is clear, however, is that anthracyclines carry significant risk of both myelosuppression and cardiotoxicity, Dr. Baruchel said. (mdedge.com)
  • Anthracyclines are effective cancer chemotherapeutic agents but can induce serious cardiotoxicity. (aspetjournals.org)
  • These results suggest that the mechanism of anthracycline-induced cardiotoxicity may involve the down-regulation of GATA-4 and the induction of apoptosis. (aspetjournals.org)
  • BACKGROUND Anthracycline chemotherapeutic agents carry the well-recognised risk of cardiotoxicity. (semanticscholar.org)
  • The mechanism of anthracycline cardiotoxicity is thought to be related to oxygen free radicals ( 10-12 ). (onlinejacc.org)
  • Clinically the most important anthracyclines are doxorubicin, daunorubicin, epirubicin and idarubicin. (wikipedia.org)
  • Daunorubicin, doxorubicin, and epirubicin are anthracyclines. (news-medical.net)
  • For patients with triple-negative breast cancer (TNBC), neoadjuvant carboplatin plus docetaxel yields the same pathologic complete response and survival rates as a standard anthracycline-based neoadjuvant regimen ― carboplatin and paclitaxel followed by doxorubicin / cyclophosphamide ― but with less toxicity, higher completion rates, and at lower cost. (medscape.com)
  • In the standard-of-care anthracycline arm, 48 women received carboplatin AUC 6 every 21 days for four cycles plus paclitaxel 80 mg/m 2 weekly for 12 weeks, followed by doxorubicin 60 mg/m 2 plus cyclophosphamide 600 mg/m 2 every 2 weeks for four cycles. (medscape.com)
  • The anthracyclines -- notably doxorubicin (Adriamycin) -- yield about a 5% improvement in survival overall, Dr. Slamon said, but they are also associated with cardiac and bone marrow morbidity and mortality. (medpagetoday.com)
  • The impact of ionizing radiation generated by a beam of electrons of 25-400 kGy on the stability of such analogs of anthracycline antibiotics as daunorubicin (DAU), doxorubicin (DOX), and epidoxorubicin (EPI) was studied. (hindawi.com)
  • The most widely used anthracyclines are doxorubicin (DOX), daunorubicin (DAU), and epidoxorubicin (EPI) [ 4 - 6 ] (Figure 1 ). (hindawi.com)
  • Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. (nih.gov)
  • Adriamycin (chemical name: doxorubicin), Doxil (chemical name: doxorubicin), and Ellence (chemical name: epirubicin) are all anthracyclines. (breastcancer.org)
  • For example, doxorubicin (DOX) and its derivative epirubicin are widely used anthracyclines to treat breast, endometrial and gastric cancers, childhood solid tumors, soft tissue sarcomas, and aggressive lymphoblastic or myeloblastic leukemia ( Ewer and Ewer, 2015 ). (frontiersin.org)
  • Using mouse models of breast cancer, we demonstrated that CD73 overexpression in tumor cells conferred chemoresistance to doxorubicin, a commonly used anthracycline, by suppressing adaptive antitumor immune responses via activation of A2A adenosine receptors. (pnas.org)
  • Since anthracyclines (such as doxorubicin and epirubicin) were introduced in the 1980s, they have been widely used as supplementary chemotherapy for breast cancer, said Dr. Alessandra Gennari, a medical oncologist at the National Cancer Research Institute in Genoa, Italy, and lead author of the study. (bio-medicine.org)
  • Daunomycin and doxorubicin were the earliest anthracyclines isolated from Streptomyces peucetius and were effective against a wide range of human cancers. (intechopen.com)
  • Doxorubicin, the most commonly used of the anthracyclines, is also the most toxic. (denvernaturopathic.com)
  • This enzyme reduces anthracyclines to its semiquinone that self oxidizes to dihydroquinone (note: if I've lost you, don't worry, it will make sense in a second) which then forms a doxorubicin aglycone. (denvernaturopathic.com)
  • This study evaluates the clinical benefit of pegylated liposomal doxorubicin (PLD) in patients with metastatic breast cancer (MBC), previously treated with conventional anthracyclines. (nature.com)
  • Anthracycline drugs like daunorubicin and doxorubicin are used to treat many types of solid tumors and blood cancers such as leukemias in adults and children. (rxpgnews.com)
  • Doxorubicin (Adriamycin), one of the drugs commonly used for the treatment of breast cancer, is in a class of medications called anthracyclines. (clinicaltrials.gov)
  • Some research has shown that statins may prevent heart damage that can be caused by anthracyclines like Doxorubicin (Adriamycin). (clinicaltrials.gov)
  • This study is for women who will be receiving the anthracycline doxorubicin (Adriamycin) as part of their breast cancer treatment. (clinicaltrials.gov)
  • The data further suggests that concurrent depletion of GATA4 and CARP in cardiomyocytes by doxorubicin contributes in large part to myofibrillar disarray and the overall pathophysiology of anthracycline cardiomyopathy. (nih.gov)
  • Neoadjuvant chemotherapy is sometimes paired with anthracyclines, such as daunorubicin, doxorubicin, and epirubicin, to treat some types of breast cancer. (cancernetwork.com)
  • In the present study, we investigated the mechanisms of cell death induced by doxorubicin (DXR) and the novel disaccharide anthracycline MEN 10755, in a human ovarian cancer cell line (A2780). (aspetjournals.org)
  • The enhanced topo II targeting by 4-demethoxy doxorubicin analogues underscores the mechanistic diversity of anthracycline drugs. (aacrjournals.org)
  • The anthracycline drugs such as doxorubicin and daunomycin are widely used anticancer agents effective against a variety of solid tumors and hematologic malignancies ( 1 -3 ). (aacrjournals.org)
  • Unlike other topo II poisons, however, doxorubicin and daunomycin, the structural prototypes for the two main types of anthracyclines, trap very low levels of topo II cleavage complexes ( 19 , 20 ), whereas topo II targeting by some other anthracycline drugs seems more significant ( 21 ). (aacrjournals.org)
  • Weiss RB (1992) The anthracyclines: will we ever find a better doxorubicin? (springer.com)
  • Doxorubicin (DOX), an anthracycline, was administered to female Wistar rats (n = 16) every second day in a dose of 3 mg/kg for 11 days intraperitonealt. (uib.no)
  • Treatment of HL-1 cardiac muscle cells or isolated adult rat ventricular myocytes with anthracyclines such as daunorubicin and doxorubicin decreased the level of GATA-4 DNA-binding activity. (aspetjournals.org)
  • The anthracycline antibiotics, including daunorubicin (DNR) and doxorubicin (DOX), have been used for cancer chemotherapy for more than 20 years. (aspetjournals.org)
  • Anthracyclines are a group of chemotherapeutics that include adriamycin (doxorubicin), daunorubicin, idarubicin, and epirubicin. (unipd.it)
  • The search for less toxic and more effective anthracyclines has led to the discovery of nemorubicin, a doxorubicin derivative in which the amino nitrogen of the daunosamine unit is incorporated into a methoxymorpholinyl ring. (unipd.it)
  • Anthracyclines such as doxorubicin and daunorubicin can bind covalently the DNA when activated with formaldehyde. (unipd.it)
  • Moreover, anthracyclines that have intrinsic ability to form cross-links to the DNA, such as cyanomorpholinyl-doxorubicin or barminomycin, were found to exhibit high cytotoxicity comparable with the PNU. (unipd.it)
  • Parental human cervix carcinoma cells, HeLa, and its subline resistant to vinblastine, KB-V1, were exposed to doxorubicin (DOX) and the novel anthracyclines annamycin and WP903, given at the concentrations 0.2 and 2.0 μg/ml (DOX and annamycin) or 0.2 and 1.0 μg/ml (WP903). (iiarjournals.org)
  • Anthracycline-based regimens are the standard of care for neoadjuvant TNBC. (medscape.com)
  • A small retrospective study suggests that a chemotherapy regimen that includes an anthracycline may increase the risk of thinking and memory problems more than regimens that don't include an anthracycline. (breastcancer.org)
  • Continued research regarding the mechanisms by which anthracyclines disrupt neurocircuitry could help identify interventions that will protect against anthracycline-associated neurotoxic effects without reducing the anticancer efficacy of these regimens. (breastcancer.org)
  • Because anthracycline-based chemotherapy regimens are standard treatment for TNBC, we investigated the relationship between CD73 and anthracycline efficacy. (pnas.org)
  • Cytotoxic chemotherapy, particularly anthracycline-based regimens, therefore remains the mainstay of treatment for TNBC today. (pnas.org)
  • As a result, anthracyclines-based regimens have been long regarded as the standard therapeutic option in the vast majority of early breast cancer patients. (bio-medicine.org)
  • In those women with tumors that were HER2-positive, the anthracyclines produced a greater reduction in risk of relapse or death than non-anthracycline regimens, the study found. (bio-medicine.org)
  • The recent focus on the use of anthracyclines in early-stage breast cancer has been sparked by the availability of newer non-anthracyline-containing regimens that appear to be equally effective but that do not have the potential for serious long-term toxicities associated with anthracyclines. (cancernetwork.com)
  • 1] However, do we really have definitive evidence that anthracycline-based regimens are superior to CMF in patients with early-stage breast cancer? (cancernetwork.com)
  • however, our experience with this regimen is considerably shorter than our experience with anthracycline-based regimens. (cancernetwork.com)
  • The risk of serious cardiac damage has spurred the implementation of competing non-anthracycline regimens, although many patients still benefit from anthracyclines based on risk or underlying biology of the tumor. (aacrjournals.org)
  • This may help predict the clinical outcome of patients with locally advanced HER2-overexpressing breast cancer who were treated with chemotherapeutic regimens minus anthracyclines. (cancernetwork.com)
  • This joint analysis pooled patients from three large trials and compared several taxane-plus-anthracycline regimens (TaxAC) with a non-anthracycline-based control arm of six cycles of docetaxel plus cyclophosphamide (TC). (ascopost.com)
  • And there have been challenges in evaluating ways to de-escalate taxane-plus-anthracycline regimens through the elimination of anthracyclines. (ascopost.com)
  • 2 "This established docetaxel plus cyclophosphamide as an effective non-anthracycline regimen appropriate for comparing with taxane plus anthracycline regimens," said Dr. Blum. (ascopost.com)
  • US Oncology Research and NSABP collaborated with separate sponsors on three independent clinical trials, which randomized women with resected high-risk, early-stage breast cancer to receive docetaxel plus cyclophosphamide × 6 or one of several standard taxane-plus-anthracycline regimens. (ascopost.com)
  • A joint analysis of three large early breast cancer trials compared various taxane-plus-anthracycline regimens with docetaxel plus cyclophosphamide and confirmed the superiority of anthracyclines in high-risk early-stage breast cancer patients. (ascopost.com)
  • P = .04), demonstrating that docetaxel plus cyclophosphamide × 6 is significantly inferior to the anthracycline and taxane-containing regimens. (ascopost.com)
  • 1,2 Eribulin was previously approved for treatment of patients with metastatic breast cancer who have received at least two chemotherapeutic regimens for metastatic disease and prior treatment with an anthracycline and a taxane in the adjuvant or metastatic setting. (ascopost.com)
  • In the chemotherapy-sensitive basal-like tumors, no added benefit was detected with anthracycline substitution, suggesting that nonanthracycline regimens should be further investigated in this subtype. (aacrjournals.org)
  • Our results suggest that patients with basal-like and luminal A tumors might be safely spared of anthracycline-based chemotherapy regimens and their side effects. (aacrjournals.org)
  • Anthracyclines were introduced in the late 1970s, and have become a mainstay for ALL therapy in both children and adults, but the evidence for including them in induction regimens has been weak, Dr. Baruchel said. (mdedge.com)
  • High BCL2 expression predicted poor relapse free survival (RFS) in patients treated with adjuvant anthracycline-based regimens (log-rank p = 0.035, hazard ratio, HR 2.37, 95% CI 1.04-5.41) and a trend to poor overall survival (OS) (log-rank p = 0.085). (linkos.cz)
  • Most used regimens of chemotherapy in included studies were CMF (cyclophosphamide, methotrexate, and fluorouracil) or anthracycline-based. (biomedcentral.com)
  • Anthracycline-based regimens have proven to be one of the most effective treatments in this setting. (nottingham.ac.uk)
  • In Bonadonna G (ed) Advances in anthracycline chemotherapy epirubicin. (springer.com)
  • Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer. (sigmaaldrich.com)
  • We used in vitro and in vivo models of TNBC using cell lines sensitive to epirubicin and other anthracyclines, as well as derivative lines, resistant to the same drugs. (sigmaaldrich.com)
  • 96.9 % patients were treated with epirubicin as an anthracycline agent. (biomedsearch.com)
  • Methods and Results This report encompasses 121 women included in the 2×2 factorial, placebo‐controlled, double‐blind PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) trial with metoprolol and candesartan given concomitantly with anticancer therapy containing the anthracycline, epirubicin (total cumulative dose, 240-400 mg/m 2 ). (ahajournals.org)
  • 1985) Comparative activity and toxicity of adriamycin (ADM) and new anthracycline analogs in advanced breast cancer (abstract). (springer.com)
  • The regimen is highly active, but there is a small but serious risk for cardiomyopathy and leukemia with anthracycline/cyclophosphamide. (medscape.com)
  • We're just now, with modern technology, being able to get a handle on some of these complications," he said at the press conference, noting that devastating cardiomyopathy has plagued anthracycline use for over 30 years. (medpagetoday.com)
  • They found that higher cumulative anthracycline exposure was associated with increasing odds of cardiomyopathy. (medpagetoday.com)
  • For patients who would receive higher doses of anthracycline, such as those with bone tumors, sarcomas, or acute myeloid leukemia, cardiomyopathy risk is high no matter what the gene status. (medpagetoday.com)
  • Despite this, the precise mechanisms and the ability to reliably predict who exactly will go on to develop cardiomyopathy and heart failure in the face of anthracycline exposure or childbirth have proven elusive. (medworm.com)
  • Shan and colleagues [1] provided a thorough, insightful, and well-balanced review of anthracycline cardiomyopathy. (annals.org)
  • Disruption of a GATA4/Ankrd1 signaling axis in cardiomyocytes leads to sarcomere disarray: implications for anthracycline cardiomyopathy. (nih.gov)
  • Anthracyclines and chest irradiation are known to cause cardiomyopathy and progressive heart failure (HF), requiring advanced therapies. (acc.org)
  • Current protocols of anthracycline-induced cardiomyopathy in rabbits present with high premature mortality and nephrotoxicity, thus rendering them unsuitable for studies requiring long-term functional evaluation of myocardial function (e.g., stem cell therapy). (hindawi.com)
  • Thus, a shortened protocol of anthracycline-induced cardiomyopathy as in DAU4 group results in high incidence of overt dilated cardiomyopathy, which insidiously progressed to congestive heart failure, associated to reduced systemic compromise and very low premature mortality. (hindawi.com)
  • The American Heart Association (AHA) recommends routine surveillance, early diagnosis and treatment of anthracycline-based chemotherapy (AC) induced cardiomyopathy (AC-CMP). (bmj.com)
  • Comprehensive single institution approach of using evidence-based guidelines to evaluate real-world surveillance and management patterns of patients with lymphoma with anthracycline-based chemotherapy-induced cardiomyopathy. (bmj.com)
  • Despite numerous investigations, the causes underlying anthracycline cardiomyopathy are yet to be established. (aspetjournals.org)
  • Following organizations serve the condition "Cardiomyopathy due to Anthracyclines" for support, advocacy or research. (diseaseinfosearch.org)
  • Finding the right clinical trial for Cardiomyopathy due to Anthracyclines can be challenging. (diseaseinfosearch.org)
  • The terms "Cardiomyopathy due to Anthracyclines" returned 0 free, full-text research articles on human participants. (diseaseinfosearch.org)
  • Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy. (diseaseinfosearch.org)
  • According to ClinicalTrials.gov there are currently 0 additional "open" studies for "Cardiomyopathy due to Anthracyclines" (open studies are recruiting volunteers) and 2 "Cardiomyopathy due to Anthracyclines" studies with "all" status. (diseaseinfosearch.org)
  • Early changes in cardiac tissue morphology assessable by cardiac MRI can predict the development of subsequent cardiomyopathy in sarcoma patients treated with anthracyclines. (isrctn.com)
  • The incidence and severity of anthracycline-induced cardiomyopathy is associated with the cumulative dose of the chemotherapeutic agent. (onlinejacc.org)
  • Once clinically apparent, anthracycline-induced cardiomyopathy is often irreversible and potentially lethal ( 3-6 ). (onlinejacc.org)
  • Anthracycline antibiotics belong to the group of anticancer drugs. (hindawi.com)
  • Given the considerable exposure of medical personnel to anthracycline antibiotics and their adsorption to most surfaces, especially those of sterilization filters, there is a need to find new sterilization methods that do not rely on filtration. (hindawi.com)
  • Stability studies demonstrated degradation of anthracycline antibiotics in solutions, under the influence of increased temperature and when exposed to light in the solid state as well as a consequence of combining chemotherapy with radiotherapy [ 10 - 15 ]. (hindawi.com)
  • Regarding the effects of radiation sterilization on anthracycline antibiotics, only DOX was studied in that respect with a focus on the impact of a standard dose of 25 kGy on its stability [ 16 ]. (hindawi.com)
  • Anthracyclines technically are also antibiotics, although their high toxicity precludes their use as such. (wikidoc.org)
  • Anthracyclines were primarily recognized as antibiotics due to their antibacterial properties in 1939 [ 1 ]. (intechopen.com)
  • Cellular effects of the anthracycline antibiotics involve an interplay of noncovalent DNA intercalation, formation of covalent DNA adducts, topoisomerase II (topo II) poisoning, and free radical effects on cellular membranes and DNA ( 2 -4 , 6 -9 ). (aacrjournals.org)
  • The efficiency of anthracycline antibiotics, interpreted as cytotoxic action, was dependent on cell type. (iiarjournals.org)
  • Most of those components are antitumor agents and anthracycline antibiotics active against Gram-positive bacteria. (wikipedia.org)
  • A wireless device designed for detection of heart dysfunction in childhood cancer survivors treated with anthracycline chemotherapy was accurate and displayed a low false-negative rate as compared to cardiac magnetic resonance imaging. (news-medical.net)
  • Conclusions In this analysis of female patients with breast cancer treated with anthracycline chemotherapy, statin use was associated with a lower risk for incident HF. (onlinejacc.org)
  • Long-term cardiac damage from low-dose anthracycline use for childhood cancers was substantially higher among carriers of a variant in the CBR1 and CBR3 genotype, found Smita Bhatia, MD, MPH, of City of Hope National Medical Center in Duarte, Calif., and colleagues. (medpagetoday.com)
  • All of the anthracyclines drugs cause dose dependent cardiac toxicity. (denvernaturopathic.com)
  • In the mitochondria of cells other than cardiac cells, the anthracyclines cannot get all the way in to the inner core of the mitochondria. (denvernaturopathic.com)
  • When the Co Q-10 gets displaced in the cardiac mitochondria, the anthracycline metabolites go to work injuring the inside of the mitochondria through oxidative damage. (denvernaturopathic.com)
  • It turns out that administering Co Q-10 prior to treatment with anthracyclines prevents the damage to cardiac mitochondria. (denvernaturopathic.com)
  • These anthracycline drugs create irreversible damage to the cardiac mitochondria. (denvernaturopathic.com)
  • Clinical evaluation, echocardiogram, and measurement of cardiac biomarkers were conducted at baseline, the end of anthracycline-based chemotherapy, and at three and nine months after anthracycline-based chemotherapy. (empr.com)
  • Patients that received an anthracycline were five times more likely to develop cardiac symptoms ( 2 ). (aacrjournals.org)
  • As the authors have correctly stated, early preclinical cardiac injury should be looked for soon after anthracycline treatment to effectively treat this disorder from its onset, before its overt clinical expression. (ahajournals.org)
  • More recent reports have shown that the prevalence of cardiac abnormalities is much lower with cumulative anthracycline doses of less than 250-300 mg/m 2 . (bmj.com)
  • Cardiac toxicity is a common complication of anthracycline-based chemotherapy (AC), with the clinical course ranging from transient asymptomatic left ventricular dysfunction (LVD) to chronic heart failure (HF) and even cardiac death. (bmj.com)
  • To determine whether decreased GATA-4 levels are functionally related to cardiac muscle cell death that can be induced by anthracyclines, the ability of ectopic GATA factors to rescue anthracycline-induced apoptosis was tested. (aspetjournals.org)
  • There was no association between change in biomarker concentrations and change in cardiac function during anthracycline therapy. (ahajournals.org)
  • Cardiac tissue morphology is assessed in sarcoma patients treated with anthracycline-based chemotherapy using cardiac MRI. (isrctn.com)
  • The genotype no longer appeared to impact outcomes at the highest cumulative anthracycline doses, though, Bhatia reported at a press conference in advance of her presentation at the American Society of Clinical Oncology meeting here. (medpagetoday.com)
  • The overall clinical benefit rate (objective response+stable disease ⩾ 24 weeks) was 24% (16.1% in patients with documented anthracycline resistance vs 29% in patients classified as having non-anthracycline-resistant disease). (nature.com)
  • 12 months and those who received PLD ⩽ 12 months since last anthracycline treatment for metastatic disease (clinical benefit 25 vs 24.1%, respectively). (nature.com)
  • In conclusion, PLD was associated with an evident clinical benefit in anthracycline-pretreated patients with MBC. (nature.com)
  • The present study evaluates the clinical benefit of PLD in an anthracycline-pretreated population and attempts to identify the patients who are more likely to benefit from the treatment. (nature.com)
  • The study, undertaken at the British Columbia Cancer Agency, Vancouver, found that women with early stage breast cancer treated with up to 4 courses of standard adjuvant anthracycline showed no relationship between dose intensity and clinical outcome, despite nearly a decade of follow-up. (innovations-report.com)
  • Reductions in the dose intensity (DI) of adjuvant anthracycline based chemotherapy in early stage breast cancer are frequently required due to treatment toxicity or poor tolerance, but the implications of a minimal reduction in DI on clinical outcome remain uncertain. (innovations-report.com)
  • Recognising a threshold effect of both cumulative dose and dose intensity of anthracyclines, and in light of emerging evidence that dosing schedules may impact on outcome in women with node positive breast cancer, oncologists are often concerned that any single dose modifications or delays will compromise clinical benefit. (innovations-report.com)
  • rs28714259 represents a validated SNP that is associated with anthracycline-induced CHF in three independent, phase III adjuvant breast cancer clinical trials. (aacrjournals.org)
  • The clinical benefit and safety of the EGFR tyrosine kinase inhibitor gefitinib ('Iressa') 1 was evaluated in this Phase II, multicentre study of patients with taxane and anthracycline pretreated, metastatic breast cancer. (springer.com)
  • This study confirms that an anthracycline-free neoadjuvant chemotherapy regimen for patients with locally advanced HER2-positive breast cancer can be safely used without compromising clinical outcome, provided that trastuzumab is given concurrently with a weekly taxane. (cancernetwork.com)
  • 7- con-O -Methylnogaril (menogaril, NSC-269148) is a new anthracycline antibiotic that has been evaluated in a Phase I clinical trial. (aacrjournals.org)
  • Further, we examined mRNA changes induced by anthracyclines in locally advanced breast cancers biopsied before and after treatment in two clinical trials. (uib.no)
  • The DECT trial is a phase II clinical trial of patients with locally advanced or operable HER-2 breast cancer treated with taxanes and concurrent anthracyclines and trastuzumab. (oncologynurseadvisor.com)
  • Together, we provide evidence that elevated miR-125b and 141 expression predicts a poor clinical responsiveness of taxane-anthracycline-based neoadjuvant chemotherapy. (jcancer.org)
  • Here, we tested the predictive value of intrinsic subtypes on clinical trial specimens from premenopausal women with node-positive breast cancers, who were randomized to anthracycline (CEF) versus nonanthracycline (CMF) chemotherapy. (aacrjournals.org)
  • ATLANTA - Children with standard-risk B-lineage acute lymphoblastic leukemia can be safely spared from at least some of the toxicity associated with anthracyclines, the results of a randomized clinical trial suggest. (mdedge.com)
  • 20% of patients treated with anthracyclines ( Singal and Iliskovic, 1998 ), causing a significant clinical problem. (aspetjournals.org)
  • The search for a "better anthracycline" has resulted in more than 2000 analogs, but only a few more anthracyclines have attained clinical approval. (unipd.it)
  • Introduction: Pre-clinical data suggest p53-dependent anthracycline-induced apoptosis and p53-independent taxane activity. (strath.ac.uk)
  • The recent launch of dexrazoxane (Savene TM) as a licensed product for the treatment of anthracycline extravasation is to be welcomed as a very positive step in the development of both the science and clinical management of extravasation injuries. (extravasation.org.uk)
  • As certain cytotoxic antineoplastic agents, such as anthracyclines, generate reactive oxygen species as a by-product of their mechanism of action, we examined whether redox protein expression was involved in the response to anthracycline-based chemotherapy and with clinical outcome. (nottingham.ac.uk)
  • Our study does, however, provide a very effective alternative for patients and providers who want to use or prefer an anthracycline-sparing neoadjuvant chemotherapy regimen. (medscape.com)
  • The toxicity profile of the anthracycline regimen was comparable to those in previous reports. (medscape.com)
  • Anthracyclines are the backbone of childhood cancer treatment, incorporated in the regimen for over half of these cases, Bhatia said. (medpagetoday.com)
  • Of the trials that have addressed this question, only one[4] demonstrated that an anthracycline-containing regimen was significantly superior to CMF, and a meta-analysis of all these trials was required to confirm a modest benefit for anthracyclines. (cancernetwork.com)
  • 2] As Dr. Henderson states, this was a small trial that was somewhat underpowered overall and that clearly was underpowered with regard to addressing the issue of which patients really do not require an anthracycline-based regimen. (cancernetwork.com)
  • In contrast to trials of patients with unselected breast cancers, Breast Cancer International Research Group (BCIRG) trial 006[3] randomly assigned patients with HER2 gene-amplified breast cancers to treatment with either AC followed by docetaxel plus trastuzumab, or a non-anthracycline-containing regimen comprised of docetaxel, carboplatin, and trastuzumab (TCH). (cancernetwork.com)
  • Lead author Dr Anna Tinker noted that "while there is a breadth of chemotherapy options (e.g. anthracycline based, anthracycline and taxane based, dose dense) the anthracycline based regimen remains a commonly used form of chemotherapy. (innovations-report.com)
  • This retrospective analysis compared anthracyclines (as part of an induction regimen) in 128 newly diagnosed FLT3-ITD-mutated AML patients. (bioportfolio.com)
  • Presented at the 2016 ASCO Annual Meeting, the joint analysis of the ABC trials validated taxane plus anthracycline as the preferred regimen for high-risk patients. (ascopost.com)
  • Statistical noninferiority of the non-anthracycline regimen could not be demonstrated," said Joanne L. Blum, MD, PhD , of Texas Oncology at the Baylor-Sammons Cancer Center in Dallas. (ascopost.com)
  • On January 28, 2016, eribulin mesylate (Halaven) was approved for treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. (ascopost.com)
  • We found that intrinsic subtypes by qRT-PCR-based PAM50 assay, particularly the HER2-E subtype, can provide significant additional predictive value to select patients who benefit the most from an adjuvant anthracycline-based chemotherapy regimen. (aacrjournals.org)
  • The 5-year overall survival rate among children with B-cell lineage acute lymphoblastic leukemia (ALL) treated without daunorubicin in the induction regimen was 98%, compared with 97.3% of those who received the anthracycline, Dr. Andre Baruchel reported at the annual meeting of the American Society of Hematology. (mdedge.com)
  • Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma. (chu-brest.fr)
  • The anthracyclines are among the most effective anticancer treatments ever developed and are effective against more types of cancer than any other class of chemotherapeutic agents. (wikipedia.org)
  • Anthracyclines remain some of the most widely used chemotherapeutic agents but their potential is limited by its dose-limiting toxicities. (wikipedia.org)
  • Anthracyclines are a class of chemotherapeutic agents based upon samine and tetra - hydro - naphthacene - dione . (wikidoc.org)
  • Anthracyclines are among the most effective chemotherapeutic agents in the treatment of numerous malignancies. (cochrane.org)
  • However, the majority of pretreated patients with MBC had been exposed to anthracycline- and taxane-based therapies either in the adjuvant or in the metastatic setting. (nature.com)
  • TP53 status was correlated to response to neoadjuvant anthracycline/taxane-based chemotherapy with or without carboplatin and trastuzumab/lapatinib in HER2-positive and bevacizumab in TNBC. (oncotarget.com)
  • The 126 patients enrolled in the single-arm Phase II study (CA163081) had heavily pretreated, advanced metastatic breast cancer, which had progressed through three prior therapies (anthracycline, taxane and capecitabine). (drugs.com)
  • A Randomised Controlled Phase II Trial of Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine in Anthracycline-pretreated Women With Metastatic Breast Cancer. (knowcancer.com)
  • metastatic breast cancer that has been previously treated with an anthracycline and/or a taxane. (bioportfolio.com)
  • Determine the anti-tumor activity of erlotinib and gemcitabine in patients with metastatic breast cancer previously treated with anthracycline and/or taxane. (bioportfolio.com)
  • Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane. (ebscohost.com)
  • Second, the toxicity profile of anthracyclines, especially the risk of long-term complications in patients whose breast cancer has been cured, is well established. (cancernetwork.com)
  • Anthracycline-induced congestive heart failure (CHF) is a rare but serious toxicity associated with this commonly employed anticancer therapy. (aacrjournals.org)
  • Despite substantial antitumor activity, anthracyclines are not without toxicity. (aacrjournals.org)
  • One of the greatest challenges in these patients has been combining trastuzumab with extremely effective drugs such as anthracyclines at the cost of an acceptable toxicity. (oncologynurseadvisor.com)
  • We have analyzed several members of drug-metabolizing enzymes (DMEs) and other polymorphisms in genes implicated in tumor aggressivity regarding possible links between specific genetic variability in systemic drug bioavailability and toxicity in breast cancer patients treated with adjuvant anthracycline-based treatment. (cun.es)
  • Our results suggest that GSTP1 and MTHFR genotypes may be consider relevant and independent factors of toxicity in adjuvant anthracycline-based treatment of breast cancer. (cun.es)
  • Our study provides convincing statistical evidence that the added benefit of adjuvant chemotherapy with anthracyclines is confined to women who have breast tumors in which HER2 is overexpressed or amplified," she said. (bio-medicine.org)
  • A randomized trial conducted by the Italian Sarcoma Group (ISG) provided evidence of a survival benefit in high-risk soft tissue sarcoma in adults treated with anthracycline-ifosfamide adjuvant chemotherapy ( J Clin Oncol . (targetedonc.com)
  • The prevalence of circulating tumor cells (CTCs) in patients with human epidermal growth factor receptor 2 negative, hormone receptor-positive early breast cancer after adjuvant chemotherapy was compared between anthracycline-free and anthracycline-containing treatment cohorts within the Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as well as Life Style Intervention Strategies (SUCCESS) C trial and showed no significant difference. (uni-muenchen.de)
  • The study included 187 patients with TNBC, 178 of whom were treated with adjuvant chemotherapy (164 had anthracycline-based chemotherapy). (linkos.cz)
  • The present studies demonstrate that this protective effect of hemin applies only to anthracyclines and not to other classes of antineoplastic agents. (aacrjournals.org)
  • Anthracyclines are the most effective anticancer drugs with broad cancer spectrum. (springer.com)
  • Among the different mechanisms of anticancer activity of anthracyclines, anthracycline-DNA adducts formation elicited interest related to the possibility to find safer and more efficacious anticancer drugs. (unipd.it)
  • Response-evaluable patients were defined as patients with measurable disease, as determined by the IRF, which met the resistance criteria for anthracyclines, taxanes, and capecitabine. (drugs.com)
  • Here, we explored the role of Akt signaling in anthracycline resistance. (uib.no)
  • Furthermore, co-transfection with miR-125b and miR-141 mimics increased resistance of MCF7 and BT549 cells to taxane-anthracycline induced cytotoxicity. (jcancer.org)
  • Preclinical data show an association of BCL2 expression and resistance to anthracyclines. (linkos.cz)
  • Previous researches have reported that anthracycline promotes cancer cell death via regulator of G-protein signaling 6 (RGS6)-mediated activation of ataxia telangiectasia-mutated serine/threonine protein kinase and the resultant upregulation of tumor suppressor p53, leading to an apoptosis pathway underlying its cytotoxic activity. (ahajournals.org)
  • Exposure to either anthracycline induced the up-regulation of several genes known to promote cell cycle arrest and DNA repair (WAF1/p21, GADD45) or apoptosis (bax, Fas). (aspetjournals.org)
  • Although the expression of Fas was increased, an antagonistic anti-Fas antibody ZB4 did not inhibit anthracycline-induced apoptosis, suggesting that the stimulation of the Fas receptor did not play a critical role in the induction of apoptosis in this cell line. (aspetjournals.org)
  • We also observed that neither MEN 10755 nor DXR were able to induce apoptosis in A2780 cells deprived of the nucleus but retaining an intact mitochondrial function (cytoplasts) and that apoptosis induced by either anthracycline was inhibited by cycloheximide, indicating that it is an active process requiring new protein synthesis. (aspetjournals.org)
  • We conclude that, in a tumor cell line of epithelial origin, the apoptosis following exposure to anthracyclines is an active process requiring protein synthesis and drug interaction with nuclear structures. (aspetjournals.org)
  • 18F-CP18 may be useful for detection of anthracycline-induced myocardial apoptosis. (ovid.com)
  • Simultaneously, apoptosis, observed as cell morphology or phosphatidylserine translocation, was evident in both cell types exposed to the novel anthracyclines, independent of concentration. (iiarjournals.org)
  • PARP cleavage is probably not an evident marker of anthracycline-induced apoptosis which, in turn, does not seem to be the determinant in the cytotoxic action of these compounds. (iiarjournals.org)
  • Although it has been 50 years from the discovery of anthracyclines, and despite recent advances in the development of targeted therapies for cancers, around 32% of breast cancer patients, 57%-70% of elderly lymphoma patients and 50-60% of childhood cancer patients are treated with anthracyclines. (wikipedia.org)
  • Some cancers benefit from neoadjuvant anthracycline-based regimes, and these include triple negative breast cancers that do not respond well to targeted therapies due to the lack of available receptors that can be targeted. (wikipedia.org)
  • The proposed action mechanism of anthracyclines and their derivatives to exert cytotoxic effect involves the intercalation of the drug molecule into nucleic acid and inhibition of the activity of topoisomerases. (intechopen.com)
  • Experiments were performed with K562 erythroleukemia cells to further characterize the observation that hemin protects hemopoietic cells from the cytotoxic effects of anthracycline drugs. (aacrjournals.org)
  • Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. (news-medical.net)
  • Nearly all components of bohemic acid are anthracycline antibiotic agents active against Gram-positive bacteria, but not against Gram-negative bacteria, yeasts or fungi. (wikipedia.org)
  • Herein, we present a genome-wide approach for biomarker discovery with two validation cohorts to predict CHF from adult patients planning to receive anthracycline. (aacrjournals.org)
  • A primary assessment by the physician on duty, which would activate the standard departmental procedure for treatment of anthracycline extravasation. (clinicaltrials.gov)
  • The objective of this review was to assess the efficacy of different cardioprotective agents in preventing heart damage in cancer patients treated with anthracyclines. (cochrane.org)
  • Exposure of K562 cells to hemin retards the anthracycline-induced arrest of cells at the G 2 -M interphase of the cell cycle and permits cells to undergo continuing division as demonstrated by clonal growth in plasma clot cultures. (aacrjournals.org)
  • Similarly, LV restriction has been suggested to be a late functional event after anthracycline exposure. (bmj.com)
  • Left ventricular strain and strain rates are decreased in children with normal fractional shortening after exposure to anthracycline chemotherapy. (semanticscholar.org)
  • The authors also note that they did not find an association between anthracycline exposure and neuropsychological performance on any measure they examined. (technologynetworks.com)
  • Anthracyclines are active against a wide range of tumours, in particular, adriamycin is used in the treatment of breast cancer, Hodgkin's lymphoma, lung cancer, multiple myeloma and re-occurring ovarian cancer. (unipd.it)
  • These genes control synthesis of cardiotoxic alcohol byproducts from certain carbonyl reductase enzymes that metabolize anthracycline drugs, Bhatia explained. (medpagetoday.com)
  • Anthracyclines are highly effective in the treatment of childhood malignancies, but are potentially cardiotoxic at all dose ranges. (bmj.com)
  • Although current guidelines discourage from the concurrent use of trastuzumab and anthracyclines in HER2-positive breast cancer, we challenged once more the available evidence by administering a less cardiotoxic anthracycline," concluded Giordano. (oncologynurseadvisor.com)
  • Background Anthracyclines are associated with cardiotoxic effects. (ahajournals.org)
  • Preclinical investigations showed that nemorubicin, unlike classic anthracyclines, is not cardiotoxic and retains antitumour activity in various multidrug-resistant tumor models. (unipd.it)
  • They typically include a taxane with or without carboplatin plus an anthracycline/cyclophosphamide combination. (medscape.com)
  • The widespread use of anthracyclines began when these agents were shown to be superior to CMF (cyclophosphamide, methotrexate, and 5-fluorouracil). (cancernetwork.com)
  • In terms of the study's primary endpoint-invasive disease-free survival-docetaxel plus cyclophosphamide × 6 was significantly inferior to taxane plus anthracycline. (ascopost.com)
  • The comparison of docetaxel plus cyclophosphamide with taxane plus anthracycline was founded upon the pivotal USOR 9735 study of docetaxel plus cyclophosphamide × 4 vs AC × 4, which showed an overall survival superiority for docetaxel plus cyclophosphamide. (ascopost.com)
  • The analysis was designed to test noninferiority of docetaxel plus cyclophosphamide to taxane plus anthracycline with respect to invasive disease-free survival. (ascopost.com)
  • Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer. (biomedsearch.com)
  • The purpose of this study is to evaluate the efficacy and safety of docetaxel plus cyclophosphamide(TC) compared with docetaxel, anthracycline, and cyclophosphamide(TEC) in neoadjuvant treatment of triple negative or HER2 positive breast cancer. (biomedsearch.com)
  • In TNBC patients treated with anthracycline-only preoperative chemotherapy, high CD73 gene expression was significantly associated with a lower rate of pathological complete response or the disappearance of invasive tumor at surgery. (pnas.org)
  • Our goal was to determine whether autophagy inhibition improves treatment efficacy in TNBC cells in tumors either sensitive or refractory to anthracyclines. (sigmaaldrich.com)
  • Autophagy inhibition enhances therapeutic response in both anthracycline-sensitive and -resistant TNBC and may be an effective new treatment strategy for this disease. (sigmaaldrich.com)
  • These findings suggest the possibility of targeted treatment with anthracyclines in TNBC. (linkos.cz)
  • High BCL2 expression predicted poor outcome in TNBC treated with adjuvant anthracycline-based chemotherapy. (linkos.cz)
  • In patients with MBC, anthracyclines and taxanes are the most active drugs. (nature.com)
  • Currently, there are many studies being conducted in the search for anthracyclines with better anti-tumour efficacy or with reduced side effects using different nanotechnology-based drug delivery systems. (wikipedia.org)
  • Further investigation is needed to determine the efficacy of GPX-150 in anthracycline-sensitive malignancies. (sigmaaldrich.com)
  • The authors also identified an approved drug that can prevent the export of E2F7 from the nucleus and thereby restore the efficacy of anthracycline chemotherapy in head and neck cancer. (sciencemag.org)
  • Furthermore, anthracycline use varies with different protocols and risk groups, making it difficult to get a clear picture of their efficacy up front in ALL. (mdedge.com)
  • No safe dose has been established for anthracyclines in children, in part because of the significant variation between individuals in tolerability, Bhatia told the press. (medpagetoday.com)
  • But once the dose of anthracyclines got sufficiently high (above 300 mg/m 2 ) the relationship no longer held, which she explained as this mechanism getting overwhelmed by the sheer force of oxidative damage from all the unmetabolized anthracycline. (medpagetoday.com)
  • A patient's lifetime dose is calculated during treatment, and anthracycline treatment is usually stopped (or at least re-evaluated by the oncologist) upon reaching the maximum cumulative dose of the particular anthracycline. (wikidoc.org)
  • Oncologists are known to utilise haematopoietic growth factors if dose reductions or delays in adjuvant anthracycline based chemotherapy have been required. (innovations-report.com)
  • This association remained after adjusting for older age and cumulative anthracycline dose. (ajmc.com)
  • Fifteen patients receiving trastuzumab had additional follow-up at six and 12 months after the last dose of anthracycline-based chemotherapy. (empr.com)
  • The same two observers, blinded to the type of malignancy and anthracycline dose, performed the examinations and analysis. (bmj.com)
  • After follow-up for up to 5 years, patients who received full-dose anthracycline-ifosfamide chemotherapy had a relapse-free survival (RFS) probability of 62% versus 38% for patients who preoperative therapy tailored to individual tumor histology. (targetedonc.com)
  • In a population of soft tissue sarcoma patients selected by a risk of relapse averaging 60% to 70%, the neoadjuvant administration of a short, full-dose anthracycline-plus-ifosfamide chemotherapy increases relapse-free survival by more than 20% and overall survival by at least 10% at more than 3 years," said Alessandro Gronchi, MD, chair of Sarcoma Surgery at the National Cancer Institute in Milan, Italy. (targetedonc.com)
  • Full-dose neoadjuvant anthracycline+ifosfamide chemotherapy is associated with a RFS and OS benefit in localized high-risk adult STS of the extremities and trunk wall: interim analysis of a prospective randomized trial. (targetedonc.com)
  • She and her colleagues found that the rates of heart failure among adult patients receiving anthracycline therapy were significantly lower when the patients had an infusion of the drug that lasted six or more hours, compared to shorter infusions times. (rxpgnews.com)
  • Although the study included only those who received anthracyclines as children, the mechanism would likely be the same in adults, which Bhatia said her group plans to study. (medpagetoday.com)
  • A comprehensive elucidation of the molecular mechanism(s) of action of anthracyclines drugs plays a significant role in the rational drug designing to obtain an effective, selective, and safe anti-cancer drugs. (intechopen.com)
  • The ability of RGS6 to promote p53 activation in response to anthracycline is independent of RGS6 interaction with G proteins but requires ataxia telangiectasia-mutated serine/threonine protein kinase and exhibits a reactive oxygen species-dependent, DNA damage-independent, and GGL and DEP domain-dependent mechanism. (ahajournals.org)
  • Targeting topoisomerase II (topo II) is regarded as an important component of the pleiotropic mechanism of action of anthracycline drugs. (aacrjournals.org)
  • Peng X, Chen B, Lim CC, Sawyer DB (2005) The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. (springer.com)
  • The mechanism of decreased GATA-4 activity acts at the level of the GATA-4 gene, because anthracyclines caused significantly decreased levels of GATA-4 protein and mRNA. (aspetjournals.org)
  • The mechanism by which anthracyclines cause irreversible myocardial damage remains unclear but may involve the generation of reactive oxygen species (ROS), lipid peroxidation, mitochondrial impairment, and modulation of gene transcription. (aspetjournals.org)
  • The use of anthracyclines as antitumor drugs dates back to the 1970s, but the mechanism of the cytotoxicity of these compounds has long been a matter of debate. (iiarjournals.org)
  • Anthracyclines increase survival for HER2-positive tumors but not neg. (bio-medicine.org)
  • WEDNESDAY, Dec. 26 (HealthDay News)-- Chemotherapy drugs known as anthracyclines help boost survival for women with HER2-positive breast cancer who have undergone surgery, but they may not offer any survival benefit for those with HER2-negative tumors. (bio-medicine.org)
  • But, Gennari said, anthracyclines came into widespread use despite these risks, because a previous meta-analysis found they improved overall survival. (bio-medicine.org)
  • Anthracyclines are a standard therapy to treat acute cases of leukemia, and they have led to increased survival rates in these patients to the tune of 1% each year from 2006 to 2015, according to a release on the study results . (ajmc.com)
  • According to a study presented at the 2016 ESMO Congress, a technically negative trial in high-risk adult soft tissue sarcoma nonetheless produced a significant survival benefit for anthracycline-based neoadjuvant chemotherapy. (targetedonc.com)
  • Despite the survival advantage for anthracycline-based chemotherapy, the trial failed to achieve its primary objective: demonstrate a benefit from tailoring chemotherapy to tumor histology. (targetedonc.com)
  • In vitro experiments indicated that inhibition of miR-125b and miR-141 expression reduced cellular survival in response to taxane-anthracycline treatment. (jcancer.org)
  • Dr. Slamon said data from the registrational trial of trastuzumab (Herceptin), which he led, showed clearly that patients with co-amplified Topo IIa were the only ones who benefited from anthracyclines. (medpagetoday.com)
  • Development of diastolic dysfunction after treatment with anthracycline or anthracycline-plus trastuzumab chemotherapy is common," the authors write. (empr.com)
  • Effect at One Year of Adjuvant Trastuzumab for HER2+ Breast Cancer Combined with Radiation or an Anthracycline on Left Ventricular Ejection Fraction. (onmedica.com)
  • Herceptin - Trastuzumab samen met de chemo combinatie anthracycline/docetaxel en/of docetaxel/carboplatin geeft een hoog significante verbetering in de ziektevrije tijd van borstkankerpatiënten met Her2-Neu overexpressie. (kanker-actueel.nl)
  • The findings suggest that hemin prevents anthracycline-induced cytotoxicity by acting at several levels. (aacrjournals.org)
  • CHICAGO -- Genes related to anthracycline metabolism may be key to personalizing chemotherapy decisions in childhood cancers, researchers said. (medpagetoday.com)
  • Note that the researchers studied only survivors of childhood cancers but suggested that similar genetic results might be found for anthracyclines given to adults. (medpagetoday.com)
  • 1] A key issue with these older trials is that they accrued patients with breast cancers unselected for subtype, so it is not possible to discern which patients truly benefited more from an anthracycline than from CMF. (cancernetwork.com)
  • In conclusion, rapid Akt activation was observed in ER positive breast cancers which responded to anthracyclines. (uib.no)
  • Nevertheless, anthracyclines play a pivotal role in the treatment of many cancers, such as breast cancers and cancer of the connective tissue (sarcomas). (isrctn.com)
  • It should be emphasized that the majority of the patients included in these studies were adults with advanced solid tumors," van Dalen and colleagues said, noting that there are few good studies about the length of anthracycline treatment in children. (rxpgnews.com)
  • Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors. (sigmaaldrich.com)
  • In some of the early studies, only patients with HER2-positive tumors seemed to derive benefit from anthracyclines, but these subset analyses were never conclusive and were dramatically underpowered, she revealed. (ascopost.com)
  • DNR is the first anthracycline developed and has been found to be effective against acute leukemia, whereas DOX was found to be effective also against solid tumors. (aspetjournals.org)
  • Follow-up began concurrent with start of anthracycline therapy and continued until death, event of interest (undefined in the study), or study end (June 30, 2018). (ajmc.com)
  • However, the effects of anthracyclines on GATA transcription factors have not been studied. (aspetjournals.org)
  • Topoisomerase IIα (TOP2A) has been previously shown to be a possible predictive marker of benefit from anthracyclines. (cancernetwork.com)
  • Anthracyclines is a class of drugs used in cancer chemotherapy that are extracted from Streptomyces bacterium. (wikipedia.org)
  • SAN ANTONIO, Dec. 13 -- The anthracycline drugs -- long a mainstay of breast cancer chemotherapy -- only benefit a minority of women and should be mostly scrapped, a researcher said here. (medpagetoday.com)
  • Similar results have been seen in eight other studies, he said, leading to his conclusion that HER2-positive women with amplified Topo IIa are a "unique niche" in which the anthracycline drugs can be used. (medpagetoday.com)
  • That's the conclusion of a wide-ranging analysis that pooled the results of eight randomized trials that compared the drugs with non-anthracyclines and took into account the women's HER2 status. (bio-medicine.org)
  • To learn more about anthracyclines and other chemotherapy drugs, visit the American Cancer Society . (bio-medicine.org)
  • Anthracyclines drugs are used as a treatment regime to combat cancer owing to their great chemotherapeutic potential. (intechopen.com)
  • The article is about anthracyclines, a class of chemotherapy drugs. (denvernaturopathic.com)
  • These intermediates, termed cleavable or cleavage complexes, are stabilized by various drugs, including many anthracyclines, which convert topo II to a cellular poison. (aacrjournals.org)
  • Although the contributions of individual routes remain unclear, topo II-mediated DNA lesions are often singled out as a major factor in antiproliferative effects of the anthracycline drugs ( 3 , 6 , 18 ). (aacrjournals.org)
  • Such unusual combination of intercalation, covalent bonding and hydrogen bonding is referred to as the virtual cross-linkink [2], that leads to the formation of more stable complexes between the anthracyclines and the DNA, improving the drugs' cell killing ability. (unipd.it)
  • The anthracyclines have been widely studied for their interactions with cellular components and impact on cellular processes. (wikipedia.org)
  • Anthracyclines are widely used in the treatment of neoplastic diseases such as leukemia, breast cancer, and AIDS-related Kaposi's sarcoma. (hindawi.com)
  • Anthracyclines have undoubtedly improved outcomes for patients with early-stage breast cancer,[1] and these agents have been widely used for several decades. (cancernetwork.com)
  • Anthracycline-based chemotherapy is widely used in the management of breast cancer. (bioportfolio.com)
  • Anthracyclines are a widely used chemotherapeutic class but can cause life-threatening congestive heart failure (CHF). (aacrjournals.org)
  • Anthracyclines are a widely used chemotherapeutic class. (aacrjournals.org)
  • Anthracyclines are widely used for the treatment of patients with breast cancer ( 1 ). (onlinejacc.org)
  • In the current trial, one woman in the anthracycline arm died of secondary acute myeloid leukemia . (medscape.com)
  • If validated, the results suggest that those who would require lower doses of anthracyclines -- typically children with acute lymphoblastic leukemia or non-Hodgkin's lymphoma -- and test positive for the genotype might be considered for a different chemotherapeutic class, Bhatia said. (medpagetoday.com)
  • In cases of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), there is a greater risk of symptomatic heart failure in the first year following initiation of anthracycline treatment. (ajmc.com)
  • Owing to scarce knowledge regarding the connection between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and risk of heart failure (HF) from anthracycline use in chemotherapy, researchers from the Hospital of the University of Pennsylvania (HUP) wanted to develop a risk score to help oncologists stratify their highest-risk patients. (ajmc.com)
  • Symptomatic heart failure in acute leukemia patients treated with anthracyclines. (ajmc.com)
  • Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia. (bioportfolio.com)
  • Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia. (bioportfolio.com)
  • We have recently reported that acute treatment with anthracyclines inhibits membrane-associated calcium-independent phospholipase A 2 (iPLA 2 ) activity both in vitro and in vivo. (aspetjournals.org)
  • 72% of the women in the anthracycline arm completed 10 or more doses of paclitaxel, and 85% completed all four carboplatin doses. (medscape.com)
  • It is the standard by which novel anthracyclines are judged. (wikipedia.org)
  • The first anthracycline discovered was daunorubicin (trade name Daunomycin), which is produced naturally by Streptomyces peucetius, a species of actinobacteria. (wikipedia.org)
  • Comparison of Neurocognitive Function After Anthracycline-Based Chemotherapy vs Nonanthracycline-Based Chemotherapy. (technologynetworks.com)
  • Now, he said, anthracycline-based adjuvant treatment should be reserved for women who don't have access to therapy targeted to the HER2 receptor, which doesn't apply to women in the U.S. (medpagetoday.com)
  • Instead, he said, it's a question of timing: "Most people feel they'll be using a lot less in the way of anthracycline-based therapy in the years ahead," he said, "and there are some people who are running to that goal post. (medpagetoday.com)
  • Patients were considered anthracycline resistant when they had disease progression on anthracycline therapy for MBC or within 6 months of adjuvant therapy. (nature.com)
  • Based on these results, we believe that there is a rational basis for the use of PLD as a second-, third-, or fourth-line therapy in patients with MBC after anthracycline and/or taxane failure. (nature.com)
  • Anthracycline therapy can be very successful at controlling cancer, but heart damage caused by anthracycline treatment "is a considerable and serious problem," said Dr. Elvira van Dalen of the Emma Children's Hospital in the Netherlands. (rxpgnews.com)
  • Recent studies have shown that the toxic heart effects of anthracycline therapy can have lasting effects on children's health. (rxpgnews.com)
  • 2014). Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients. (cancernetwork.com)
  • Cortés-Funes H, Coronado C (2007) Role of anthracyclines in the era of targeted therapy. (springer.com)
  • Anthracycline therapy was used in 18 patients. (linkos.cz)
  • TOP2A amplification, a predictive factor for anthracycline therapy response, is usually connected to HER2 amplification. (linkos.cz)
  • Compared to non-triple negative breast cancer patients, triple negative breast cancer patients have shown better response rate and higher pathological response rate with anthracycline use, an indicator used for predicting improved long-term outcomes. (wikipedia.org)
  • Utility of routine pretreatment evaluation of left ventricular ejection fraction in breast cancer patients receiving anthracyclines. (bioportfolio.com)
  • The first anthracyclines were so successful that thousands of analogues have been produced in attempts to find compounds with improved therapeutic applications. (wikipedia.org)
  • Several groups of researchers focused on designing compounds that retained the polycyclic aromatic chromophore of the anthracyclines (favouring intercalation into DNA) and substituting the sugar residue with simple side chains. (wikipedia.org)
  • Both retrospective and prospective data show that the anthracyclines only benefit women with amplification of both the HER2 receptor and the topoisomerase IIa gene (Topo IIa), Dr. Slamon told an oral session at the San Antonio Breast Cancer Symposium. (medpagetoday.com)
  • Each of the mentioned pleiotropic activities of anthracyclines probably contributes to cell growth inhibition, although their relative significance may be cell type specific and may vary for different anthracycline analogues. (aacrjournals.org)
  • The results support our hypothesis that myocardial iPLA 2 inhibition may be one of the steps that leads to the functional and structural changes associated with chronic anthracycline treatment. (aspetjournals.org)
  • The kinetic actions of drug-induced inhibition of poly(A)+-RNA appearance in the cytoplasm and inhibition of total RNA synthesis were equivalent for ADM, DNM and CMM, whereas the other anthracyclines showed different kinetics. (aspetjournals.org)
  • These studies confirm the greater sensitivity of nucleolar RNA synthesis to Class II anthracyclines in erythroleukemia cells and suggest that inhibition of post-transcriptional events may occur in cells exposed to PYM, MCM, and ACM but at higher concentrations than are required for inhibition of RNA synthesis. (aspetjournals.org)